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Chapter 1 
 
Introduction 
 
8 Chapter 1 
This thesis addresses the management of patients with cardiovascular diseases in 
primary care, particularly coronary heart disease and chronic heart failure. Despite 
extensive research on the adoption of evidence based recommendations by family 
physicians, a better understanding remains warranted of the factors associated 
with quality and outcomes of cardiovascular primary care. 
  
Cardiovascular disease 
Cardiovascular disease (CVD) is the leading cause of death worldwide and has a 
major impact on both developed and developing nations, being responsible for 
nearly 30% of all deads1. The two most prevalent CVDs are ischemic (coronary 
heart disease – CHD) and cerebrovascular diseases, which together are 
responsible of the 60% overall cardiovascular mortality2. Chronic Heart Failure 
(CHF) is a related, but different condition with high impact on mortality, quality of 
life and costs.  
Mediterranean countries are characterized by substantially lower CHD mortality 
rates compared with Northern European countries3 and the United States4 given 
similar levels of the main cardiovascular risk factors in the population (the 
"Mediterranean paradox")5. It has been hypothesized that regional factors may 
confer protection6, such as the Mediterranean diet7. Nevertheless, cardiovascular 
disease remains highly prevalent and important cause of dead in Mediterranean 
countries. In Spain CVDs account for 32% of all deaths2 (28% male, 36% female). 
CHD is the most frequent cause of death (30%) and it is higher among male (37%) 
than in female (24%). In women fatalities due to cerebrovascular disease are more 
frequent (28% in female and 25% in male). Particularly in Catalonia, in 2008, CHF 
accounted for the third cause of death (total 5.13%, women 6.75%, men 3.55%), 
after ischemic diseases (total 7.94%, women 6.93%, men 8.94%) and lung 
cancer8. In Spain, as in other developed countries, there is a reduction in overall 
cardiovascular disease mortality. In Spain this reduction has been observed since 
the seventies and is higher for cerebrovascular disease (4%) than CHD (1.2%)9. It 
has been estimated that half of this decrease can be attribute to evidence-based 
medical therapies and half to reductions in major risk factors10.  
Despite this reduction in mortality, the burden of CHD remains an important public 
health issue and also causes substantial disability, long-term dependence on 
health services and medications and loss of quality of life11. For instance, the 
hospitalization rate for CHD in Spain in 2007 was overall 317/100,000 inhabitants 
(447 in male and 189 in female)2. It is expected to become a heavier burden in the 
future due to an increase in life expectancy and improvement of survival rates 
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mainly due to implementation of evidence based therapies and risk factors 
management.  
The prevalence of CHF is between 1 and 3% in developed countries and 
increasing with age12-15. It is also a highly prevalent cause of hospitalization16,17, 
accounting for 5% of acute hospital admissions and rises in patients older than 65 
years12,18. 
CHF is a complex clinical syndrome which arises as a consequence of an 
abnormality in cardiac structure, function, rhythm or conduction19. It is 
characterized by symptoms such as exertional breathlessness and fatigue, and 
signs of fluid retention as well as signs associated with the underlying cardiac 
disorder20 of which in developed countries ventricular dysfunction is the 
commonest. 
CHF has many causes, of which CHD (systolic dysfunction) and hypertension 
(diastolic and systolic dysfunction) are the most prevalent. Consequently CHF 
does not occur in isolation. It is caused by an underlying cardiac defect or its 
cause, generally in elderly individuals, many of whom are being treated for other 
medical problems. The existence of many co-morbidities creates the potential for 
drug intolerance and interactions and poses major difficulties for their treatment. 
Furthermore most of the cardinal symptoms (dyspnoea and fatigue) and signs of 
CHF are non-specific, especially in elderly patients, and could be due to other co-
existing health problems. Therefore this complicates the diagnosis of CHF, which 
initially takes place usually in the primary care to a family physician (FP). 
Many health problems such as hypertension, hypercholesterolemia, diabetes 
mellitus and renal failure have been described to contribute to cardiovascular 
diseases. Also other risk factors related to lifestyle such as weight, diet, smoking 
and physical activity can also contribute to their prognosis. 
Management of CVD and prevention of further cardiovascular events usually takes 
place in primary care. FPs usually face complex patients who are often elderly and 
frail due to co-morbidity and polypharmacy. 
Evidence based recommendations for the management of patients with 
cardiovascular diseases are available in international clinical guidelines. Particular 
emphasis has been given to improving lifestyle (smoking cessation, physical 
exercise, diet and alcohol intake) and pharmaceutical treatment (statins, 
antihypertensive therapy and antiplatelet therapy). 
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Spanish National Health System (Spanish NHS) 
The Spanish NHS provides universal coverage and is state funded through 
general taxes. The system is divided into primary and secondary care. The 
Spanish NHS has been decentralized into 17 Autonomous Communities or 
regions that configure the Spanish State, each are in charge of health planning, 
public health and healthcare services management21. There are minor differences 
between these regions with respect of structure and administration across the 
region22. For instance, in Aragon and Navarra all services are provided by the 
state-funded regional service while in Catalonia, the provision of primary care 
services is offered by different providers (state and non-state funded) among 
which the Catalan Health Institute (ICS) is responsible for the provision of primary 
care services to the 80% of the Catalan population (7,210,508)23. In Spain, the 
health promotion and preventive activities programme (PAPPS) developed by the 
Spanish Society of Family Medicine (SemFYC) and adopted by the Spanish NHS 
has integrated the international guidelines on cardiovascular prevention activities. 
The "EUROPREV" (European Network for Prevention and Health Promotion in 
Family Medicine and General Practice) was created to extend and coordinate the 
experiences from the PAPPS program and to promote preventive services at 
European level22. 
 
Cardiovascular primary care in Catalonia 
Primary care is organized as a network of large practices that behave as 
geographical and administrative units and family physicians (from 4 to 36 
physicians per practice depending on the number of patients listed at the practice) 
are part of the staff, together with nurses, paediatricians, social workers, dentists 
and ancillary staff22. Every citizen is registered with a family physician who acts as 
a gatekeeper to specialized care. In 199024 Catalonia initiated the implementation 
of an integrated care program which consisted of medical specialists, such as 
cardiologists, providing support on patient management (diagnosis, prescription, 
follow up, continuum educational programs) to FPs in primary care practices 
(PCPs). In PCPs, components of the six dimensions of the chronic care model25, 
for chronic disease management, are implemented, particularly in ICS, the main 
data source of this thesis. (1) In relation to healthcare organization, chronic care is 
seen as a priority with procedures for the management of patient information in 
relation to examination results, alerts in the electronic medical records for 
reviewing medication prescribed, monthly and annual production of quality reports 
among others. (2) In delivery system design, management of chronic conditions 
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are planned separated from acute care (i.e. case finding methods, recall of 
patients at risk, screening programs, prevention procedures). (3) Access to 
decision support systems such as electronic clinical guidelines are embedded into 
the electronic medical records. There is also access to peer-reviewed medical 
journals and to specialist expertise (either at the practice, by email or telephone). 
(4) Clinical information systems are implemented for medical records, prescription, 
referrals, examination requests and quality and safety management. (5) The 
organization encourages PCPs to implement self-management support activities 
(i.e. availability of leaflets about cardiovascular disease, directory of prevention 
activities available locally) as well as (6) participation of primary care professionals 
in the community (offering public health and risk reduction programs in the 
community for several conditions and age groups).  
The Catalan Health Department, in partnership with health providers, patient 
representatives, professional bodies (primary care physicians and nurses), and 
other relevant associations (e.g. education and community) developed the 
National Health Care Plan. Particularly in the Health Plan 2002-2005, applicable to 
this thesis, several targets related to CVD and risk factors management were set 
up, also adopting the PAPPS developed by SemFYC. For instance reduction of 
mortality rates due to cardiovascular diseases, increase of appropriate 
prescription, better control of levels of cholesterol and systolic and diastolic blood 
pressure. Intervention programs to promote healthier life style were also set up, 
including smoking cessation, overweight and obesity and physical exercise 
targets. To ensure implementation of these standards to the whole of Catalonia, 
the health department created a new directorate for circulatory diseases in 2006. 
This directorate also included CVD management and prevention in primary care. 
This was a permanent structure managed by two cardiologists who were 
supported by an adviser committee formed by stakeholders representing health 
providers, patient representatives, professional bodies (primary care physicians 
and nurses) and other relevant associations across Catalonia. The added value of 
this directorate was its role in encouraging and supporting standards 
implementation across Catalonia. 
The ICS adopted these recommendations by developing a wide continuum 
educational program for FPs, developing specific devises for their use in their 
electronic medical record system and as standards in their pay for performance 
outcomes framework policy for primary care.  
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Current practice 
Cardiovascular diseases, such as CHD and CHF constitute an important challenge 
for the health system. These are chronic conditions of complex patients, who tend 
to be old, have co-morbidities and polypharmacy. Although international clinical 
guidelines have been published the diagnosis and treatment of many of these 
patients remains suboptimal26,27. For instance, in patients with CHF, international 
guidelines recommend widespread use of both angiotensin-converting enzyme 
inhibitors (ACEI) and beta-blockers (BB) to improve symptoms and survival unless 
a specific contraindication exists28,29. However European research showed that 
although 60% of patients were receiving an ACEI, only 20% did so in combination 
with BB suggesting a substantial short-fall in treatment.  
In many European countries the FP plays an important role in the detection, 
treatment and monitoring of patients with established CVD. Particularly, Catalonia 
has a strong primary care-orientated health care system30 acting as a first point of 
contact for patients and gatekeeper to specialist care; also it has a strong interface 
with specialist care. Primary care is conceived to be in a very good position to 
improve care delivery and outcomes of patients with an established CVD and 
service redesign such as implementation of the Chronic Care Model accounts for 
that. However there is a lack of epidemiological studies in CVD, community based, 
reporting on patient outcomes and professionals' performance and how these can 
be influenced by the implementation of chronic care management.  
This thesis addresses current practice in the management of cardiovascular 
disease in primary care and has been divided in two sections. Section I explores 
the role of a number of organizational components in the management of patients 
with an established cardiovascular disease (CHD) in Europe and particularly in 
Catalonia. Section II describes patient outcomes (survival, hospitalizations) and 
professionals performance in patients with an established cardiovascular disease 
(CHF) managed in primary care in Catalonia.  
 
Section I  Analysis of organization of coronary heart disease primary care 
 
Evidence based recommendations for improving lifestyle and pharmaceutical 
treatment have been incorporated as performance measures in several health 
quality frameworks.  
Healthcare quality management also focused not just in the content but also in the 
delivery of such recommendations31. Effectiveness of different strategies to 
improve delivery of care have been largely investigated32,33. Evidence that 
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interventions with multiple strategies do better than single interventions is 
inconclusive. The right choice of interventions and measures probably depends on 
the topic, the setting, the target group and the problems encountered34. 
Sometimes single interventions can be effective35 and in other cases a more 
complex intervention is needed36,37. Chronic conditions treated in primary care 
requires an organizational structure allowing for population-based management. In 
this thesis we focus on several aspects of practice organization: the practice size 
and a range of organizational components that have been specified in the Chronic 
Care Model (CCM). We participated in an international research project on 
cardiovascular management, called the European Practice Assessment Cardio 
Project (EPA Cardio)38. This international study allowed us to collect data on 
several practice organization factors implemented in different primary healthcare 
systems in Europe.  
Practice size is an organizational characteristic that has been found to influence 
the delivery of services in primary care39-41. However, we did not know how this 
could apply to the management of patients with chronic conditions such as 
cardiovascular diseases in terms of variation of care provided depending on 
practice size.   
The CCM is a specific primary care orientated framework designed to organize 
and improve healthcare delivery for patients with chronic diseases. The CCM has 
been promoted as a unified package with six organizational components to be 
crucial to achieve high-quality healthcare for patients with chronic diseases: 
'healthcare organization', 'delivery system design', 'decision support', 'clinical 
information systems', 'self-management support' and 'community resources and 
policies'25. Although this framework is based on some research, its positive impact 
on clinical performance needs further investigation. We draw specific attention to 
the implementation of community resources as few studies have been found to 
judge its relative effectiveness on clinical performance42.  
 
Section II Analysis of current practice in chronic heart failure primary care 
 
Primary care has an important role on the management of patients with CHF at 
population-based level. However, community epidemiological data reporting on the 
quality of CHF management in primary care at the level of patient outcomes 
(survival, hospitalizations and care received) were lacking when we initiated our 
research in 2007 in Catalonia. Most studies are clinical trials or studies including 
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patients after hospital discharge43 that do not represent the complexity of the 
management of patients with CHF in the primary care setting. 
We conducted a population-based retrospective cohort study using the data 
collected in a project published in Clinical Trials database (NCT00792402). Briefly, 
this project used a non-equivalent controlled before and after quasi-experimental 
design with a population based approach to evaluate the impact of a clinical 
practice guideline on CHF in two regions of Catalonia. For the purpose of this 
thesis, we combined data from both study arms, the intervention (urban) and 
control (rural) regions. Despite urbanization differences, both regions shared same 
organizational features22. This study offered the possibility to have access to a 
large dataset from two different settings (urban and rural) containing information 
from three regional (Catalonia) data sources: hospital admissions, mortality 
register and primary care electronic medical records. This dataset allowed a 
comprehensive evaluation of current practice in CHF management in primary care 
in our region which we present in this section.  
We collected data from 2005 to 2007 on newly diagnosed patients over 30 years 
old, registered with the diagnosis code of CHF according to the International 
Classification of Diseases Tenth Revision used in primary care.  
In this section, we describe trends on survival, hospitalization and determine the 
association of prescription of recommended treatment in patients with CHF and 
concomitant comorbidities with and without hospitalization. We also describe the 
impact of the following prognostic factors: patients' age, gender, 
hypercholesterolemia, hypertension, diabetes mellitus, ischemic heart disease, 
chronic obstructive pulmonary disease (COPD), and chronic kidney disease 
(CKD).  
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Table 1.  Overview of research questions, methods and measures of the studies presented 
in this thesis 
 
Research questions Research 
methods 
Measures Chapter 
Section I Analysis of organization of coronary heart disease primary care 
What is the actual quality of care of 
patients with coronary heart disease in 
primary care practices across 
countries? Is it associated to practice 
size? 
Observational 
study 
Medical record audit, 
practice questionnaire 
and interview 
2 
What is the influence of the various 
domains of practice organization on 
quality of care for patients with 
coronary heart disease? 
Observational 
study 
Medical record audit, 
practice questionnaire 
and interview 
3 
Do community interventions relate to 
better primary care for coronary heart 
disease patients? 
Observational 
study 
Medical record audit, 
practice questionnaire 
and interview 
4 
Section II Analysis of current practice in chronic heart failure primary care 
What are the survival trends of patients 
with CHF managed in the community in 
Catalonia (Spain)? What is the impact 
of co-morbidity on survival in the target 
population? 
Population-based 
retrospective 
cohort study 
Medical record audit 5 
What are the hospitalization trends of 
patients with CHF managed in the 
community in Catalonia (Spain)? Which 
are the patient-related predictors of 
hospital admissions, re-admissions and 
length of stay among patients with CHF 
in the target population? 
Population-based 
retrospective 
cohort study 
Medical record audit 6 
Do complex patients (according to the 
number of co-morbidities) with CHF 
receive equivalent care (prescription of 
recommended treatment) than patients 
with less complex diseases when 
managed in primary care? 
Population-based 
retrospective 
cohort study 
Medical record audit 7 
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Abstract 
Background: Primary care has an important role in cardiovascular risk 
management (CVRM) and a minimum size of scale of primary care practices may 
be needed for efficient delivery of CVRM. We examined CVRM in patients with 
coronary heart disease (CHD) in primary care and explored the impact of practice 
size. 
Methods: In an observational study in 8 countries we sampled CHD patients in 
primary care practices and collected data from electronic patient records. Practice 
samples were stratified according to practice size and urbanization; patients were 
selected using coded diagnoses when available. CVRM was measured on the 
basis of internationally validated quality indicators. In the analyses practice size 
was defined in terms of number of patients registered of visiting the practice. We 
performed multilevel regression analyses controlling for patient age and sex. 
Results: We included 181 practices (63% of the number targeted). Two countries 
included a convenience sample of practices. Data from 2960 CHD patients were 
available. Some countries used methods supplemental to coded diagnoses or 
other inclusion methods introducing potential inclusion bias. We found substantial 
variation on all CVRM indicators across practices and countries. We computed 
aggregated practice scores as percentage of patients with a positive outcome. 
Rates of risk factor recording varied from 55% for physical activity as the mean 
practice score across all practices (SD 32%) to 94% (SD 10%) for blood pressure. 
Rates for reaching treatment targets for systolic blood pressure, diastolic blood 
pressure and LDL cholesterol were 46% (SD 21%), 86% (SD 12%) and 48% (SD 
22%) respectively. Rates for providing recommended cholesterol lowering and 
antiplatelet drugs were around 80%, and 70% received influenza vaccination. 
Practice size was not associated to indicator scores with one exception: in 
Slovenia larger practices performed better. Variation was more related to 
differences between practices than between countries. 
Conclusions: CVRM measured by quality indicators showed wide variation within 
and between countries and possibly leaves room for improvement in all countries 
involved. Few associations of performance scores with practice size were found. 
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Background 
Many patients with chronic conditions are treated in primary care. This is 
challenging as high quality chronic care asks for an organizational structure 
allowing for population-based management. In previous research larger practice 
size tented to be related to higher quality of care considering various conditions 
with greater diversity of services1-5. Furthermore, larger practices tended to show 
more features consistent with the delivery of chronic care6,7. In many countries 
there is a tendency to develop larger practices8. Increasing size of scale and 
scope may be, up to a certain point, associated with decreasing average costs of a 
service as fixed costs like participation in continued education and hiring additional 
staff are divided by a larger number of patients. From an educational perspective, 
a larger size of scale with more patients may be associated with larger opportunity 
to practice specific procedures, thus steeper learning curves and higher quality of 
performance. On the other hand, a smaller practice size may have advantages in 
terms of more personal care and continuity9. 
Cardiovascular diseases (CVD) have major impact on the mortality and health-
related quality of life of people in both developed and developing countries. 
Despite a declining cardiovascular mortality, improvements in the preventive, 
medical and surgical treatment in previous decades, and widely accepted practice 
guidelines10-12, CVD are still one of the major causes of death and illness. Primary 
care can play an important role in delivering cardiovascular risk management 
(CVRM) to populations, but previous research showed that not all eligible patients 
receive optimal prevention of atherosclerosis-related CVD13,14. Many European 
countries therefore have adopted large scale programs for improving 
cardiovascular risk management, including pay-for-performance in the United 
Kingdom, disease management in Germany and practice accreditation in the 
Netherlands15. 
While data on CVRM are collected in a number of countries, mostly in specialized 
care settings13,14, comparable data from primary care where many patients are 
treated and counselled, was lacking. We conducted an observational study of 
current CVRM in primary care in eight European countries, focused on patients 
with established coronary heart diseases (CHD)16. In this paper we aimed to 
describe current practice across countries and to explore associations of practice 
size with CVRM measured by quality indicators. 
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Methods 
Data were derived from the EPA Cardio study16. In this cross-sectional 
observational study eight countries provided data on CVRM in primary care 
practices: Austria, Belgium, England, France, Germany, Netherlands, Slovenia 
and Switzerland. The country sample was a convenience sample from the 
countries participating within the EQuiP framework and included countries with a 
strong and with a weak position of primary care within the national health care 
system, and both small and large countries17. Countries with a strong primary care 
orientation were England, the Netherlands, and Slovenia; in the other countries 
primary care held a weaker position within the health care organization15,18. Data 
from patient records were gathered in 2008 and 2009. Ethical approval for the 
study has been obtained in each of the participating countries, according to 
national laws and regulations. A detailed study protocol has been published16. 
Stratified random sampling of 36 practices per country was planned, involving two 
factors: practice location (up to versus more than 100,000 inhabitants) and 
practice size (up to two versus two or more full time equivalent physicians working 
in the practice). The relative contribution of each stratum should mirror the national 
situation and each country had the option to add strata in order to better reflect the 
national context. Four countries used this possibility: in England large practices 
were split in up to and more than five GPs; in the Netherlands small practices were 
split in single handed and duo; and in Germany and Slovenia the stratum up to 
100,000 inhabitants was split in up to and more than 40,000 inhabitants. The 
number of practices – in relation to the patient numbers ‒ was based on 
calculations of statistical accuracy, as described in the study protocol based on the 
detection of significant differences between indicator scores between two 
countries16. It was calculated that 36 practices per country with data on 15 patients 
per practice would suffice for this goal. Furthermore, earlier experiences with 
international comparative data showed that 30-40 practices can provide a 
reasonably good representation of the national situation19. 
 
Patient population  
We aimed at including 15 patients with established CHD per practice, including 
patients with myocardial infarction, angina pectoris or coronary interventions. 
Patients with diabetes were excluded because diabetes care and care for CHD 
patients are largely congruent. With diabetes patients included our results in part 
would be determined by diabetes care. In each practice a list of eligible patients 
was made, preferably based on coded diagnoses in the data files of patients 
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registered with the practice. Then a random sample of 30 patients was taken from 
this list of CHD patients anticipating a 50% response rate. As variation across 
countries was anticipated related to the possibilities to generate patient lists, as 
second choice, other methods were allowed, for instance going through patient 
lists or simply by recalling patients. In Belgium, England, the Netherlands and 
Slovenia patient selection was exclusively based on recorded diagnoses. Apart 
from coded diagnoses, in Germany and Switzerland, the GP selected extra 
patients by recalling CHD patients in practices with less than 30 patients with a 
coded diagnosis of CHD. In two countries it appeared impossible to select patients 
based on coded diagnoses. In Austria, patient selection was based on going 
through prescription lists. In France, primary care physicians included eligible 
patients when they visited the practice. For this study we excluded practices with 
data on less than 8 CHD patients. 
 
Measures 
Measures were linked to a set of rigorously developed performance indicators for 
CVRM20. To develop these indicators we used a RAND Modified Delphi procedure 
with two rounds of consensus, with 101 general practitioners from nine countries 
involved in the consensus process. From an original list of 650 indicators derived 
from the scientific literature, we first identified and edited 186 unique indicators. 
After two rounds of consensus 17 indicators relevant for patients with established 
CHD were selected; for 11 out of these 17 indicators data could be collected by 
extraction from medical records. These indicators comprised the registration of risk 
factors (smoking status, physical activity capacity, weight or body mass index, 
blood pressure, and serum cholesterol), advice on physical activity, influenza 
vaccination, antiplatelet and statin drug therapy prescribed or offered, systolic and 
diastolic blood pressure below threshold (140 and 90 mmHG respectively). 
Though not identified as a key-indicator we also present data on LDL-cholesterol 
levels because these data are widely seen as an important treatment goal10-12. All 
measures were systematically translated into the different countries’ languages, 
with established procedures of forward and backward translation and a pilot 
testing. The final instrument to collect the data from the patient records was tested 
and adapted in a pilot project in five countries including two practices21.  
 
Analysis 
We calculated descriptive figures per practice providing data on practice size and 
CVRM. For each practice the percentages of patients with a positive score on 
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indicators were assessed; patients with a missing value were excluded for this 
outcome measure. We determined the mean scores across practices per country 
with standard deviations, implying that each practice had equal weight irrespective 
of the number of patients included. We tested whether the country means deviated 
significantly from the grand mean, using two-sided t-tests considering Levine's test 
results. As the analyses of country differences are explorative a threshold value of 
p<0.01 was chosen to reduce the possibility of chance capitalization. 
Based on the reported practice size ‒ patient list size when available, otherwise 
yearly attending patient numbers ‒ using a logistic multilevel regression analysis 
we assessed the association between indicator scores and practice size per 
country with two levels: a patient and a practice level. Age and gender were 
independent variables in the first level (patient level). In these analyses practice 
size was based on patient number as a continuous factor and not on the number 
of GPs in the practice what was used only for easy definition of stratification 
groups. 
Furthermore, we performed a three level logistic regression analysis with country 
as a fixed factor in the third level. For this analysis we standardized practice size 
per country. With this methodology we corrected for the differences in practices 
sizes between the countries as we were not interested in country differences but in 
the effect of practices size across countries. Furthermore, this transformed patient 
numbers to comparable data in all countries, even comparing countries with 
numbers from patients lists and countries with numbers of attending patients. We 
assessed the association between practice size and indicator scores across all 
countries and across the countries with a strong and a weak primary care system 
apart. Related to practice size we hypothesized that larger practices would perform 
better; for these hypothesis driven analyses we used p<0.05 as threshold for 
significance. 
We assessed the contribution of practices and of countries to the variance in 
scores on the performance indicators. The Intra Class Coefficients were computed 
based on the methodology described by Twisk22. 
SPSS 16 was used for descriptive analysis and t-tests, SAS for random coefficient 
regression modelling. 
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Results 
In several countries it appeared impossible to include 36 practices. Finally 232 
practices participated (81% of the number aimed at). We excluded 51 practices 
because they did not provide data on practice size (n=14), included less than eight 
CHD patients (n=33), or both (n=4). In this study we included 181 practices. In 
Austria and Switzerland a convenience sample of practices participated; in 
Belgium, additional to practices from a list, four practices were included after they 
were personally contacted by the researchers. All other countries worked with 
national or regional practice lists. Practices in Austria, Germany, and Switzerland 
reported on the yearly attending population; in the other countries practice size 
was based on the number of patients listed. 
The 181 practices included provided data on 2960 patients, on average 16.4 per 
practice. Overall 33% of the patients included were female and the overall mean 
age was 68.7 years (see Table 1). 
 
Table 1.  Practice sample and demographic data 
 
 Practices 
(n) 
Mean practice size 
(SD) 
Patients 
(n) 
% female Mean age 
(years) 
Austria 23 2878* (1369) 293 36 71.6 
Belgium 18 3035 (2363) 232 25 66.7 
England 32 6573 (3655) 479 39 68.2 
France 9 1417 (754) 133 26 67.8 
Germany 13 4423* (1608) 248 35 70.0 
The Netherlands 34 3183 (1215) 495 29 69.3 
Slovenia 35 2059 (804) 805 36 68.3 
Switzerland 17 3449* (2537) 275 24 68.2 
total 181 3538 (2582) 2960 33 68.7 
* Practices size provided by practices as number of yearly attending patients; in all other countries as 
number of patients listed. 
 
Cardiovascular risk management  
Regarding cardiovascular risk factor recording, the percentage of missing values 
was consistently 3 to 4%. The mean practice score of recording physical activity 
capacity was, on average, about 50% (see Table 2). Overall, blood pressure 
recording had the highest score (94%), followed by cholesterol levels (87%). 
Standard deviations are indicative of the differences between practices. 
Indicators concerning achievement of target values for SBP, DBP and LDL, 
considering the most recent measurements, are displayed in Table 3. We had data 
of about 90% of the patients. Overall, the mean practice score on the indicator 
DBP below 90 mmHg was 85%, and on SBP and LDL cholesterol about 45%. On 
average the scores on the recommended cholesterol lowering and anti-platelet 
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drug treatment were 80%. The practice mean score on influenza vaccination was 
less than 70%. 
Risk factor recording in general was below the mean in the Netherlands; in 
England most factors were recorded significantly more often. The other countries 
showed less deviations from the grand mean scores (see Table 2).  
 
Table 2.  Indicator scores: risk factor recording 
 
  Smoking status Physical activity 
capacity 
Weight / BMI Blood pressure Serum 
cholesterol
Austria Mean 100↑ 50.6 61.4 94.2 95.7↑ 
 SD 0 31.2 33.0 7.1 6.0 
 p .000 .566 .311 .957 .000 
Belgium Mean 76.7 52.6 84.4↑ 98.0↑ 95.4↑ 
 SD 29.0 34.5 15.1 4.2 6.7 
 p .708 .805 .001 .004 .000 
England Mean 94.8↑ 64.1 82.9↑ 98.3↑ 94.6↑ 
 SD 10.0 29.4 22.1 3.4 7.5 
 p .000 .121 .003 .000 .000 
France Mean 79.4 46.0 90.9↑ 96.2 96.4↑ 
 SD 21.5 39.6 11.0 7.7 6.7 
 p .983 .439 .000 .555 .002 
Germany Mean 92.5↑ 55.6 65.2 96.3 94.2↑ 
 SD 9.9 41.5 33.3 7.0 8.9 
 p .001 .933 .662 .462 .016 
Netherlands Mean 57.2↓ 41.7↓ 44.6↓ 82.0↓ 67.2↓ 
 SD 28.3 27.7 27.3 15.8 19.5 
 p .000 .030 .000 .000 .000 
Slovenia Mean 76.5 60.0 70.8 97.4↑ 83.6 
 SD 26.2 29.0 25.0 67 14.4 
 p .580 .358 .705 .021 .253 
Switzerland Mean 65.4 62.8 71.4 96.6 87.8 
 SD 38.1 34.8 24.4 5.9 10.8 
 p .162 .323 .727 .324 .830 
Total Mean 79.3 54.6 68.8 94.1 86.9 
 SD 27.5 32.2 28.8 10.4 16.0 
Mean practice scores (%) per country and across countries with standardized variation. Scores significantly 
deviating from the mean of all countries are marked, with p values displayed. 
 
Considering the outcomes advice on physical activity, influenza vaccination, 
antiplatelet and statin drug therapy, blood pressure and cholesterol levels (see 
Table 3) England again scored above the mean in 4 of the 7 outcomes. Here the 
Netherlands and Slovenia outperformed on one outcome, respectively influenza 
vaccination and antiplatelet drug therapy.  
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Table 3.  Indicator scores 
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Austria Mean 61.1 49.9 ↓ 86.4 78.8 46.7 86.0 59.1↑ 
 SD 30.8 29.2 25.1 22.5 20.9 9.5 22.5 
 p .062 .012 .739 .317 .850 .871 .022 
Belgium Mean 39.3 90.7↑ 90.1 85.8 55.4 85.0 46.6 
 SD 32.1 12.2 12.3 12.2 21.3 12.6 16.3 
 p .317 .000 .553 .427 .065 .870 .816 
England Mean 481 87.3↑ 90.8 90.2↑ 43.3 95.7↑ 65.5↑ 
 SD 30.7 14.4 10.5 10.8 14.8 5.1 15.1 
 p .917 .000 .171 .002 .404 .000 .000 
France Mean 45.7 50.7 88.0 86.4 61.4↑ 90.2 38.9 
 SD 39.0 31.9 15.3 21.4 18.3 10.7 19.6 
 p .876 .114 .966 .513 .029 .260 .247 
Germany Mean 56.3 74.9 69.3↓ 69.5↓ 52.3 81.2 37.1 
 SD 45.0 31.4 25.4 17.1 20.5 10.8 13.8 
 p .497 .520 .023 .006 .282 .204 .090 
Netherlands Mean 28.8↓ 96.8↑ 82.8 77.9 28.9↓ 81.0↓ 43.0 
 SD 22.9 5.8 18.2 15.9 15.6 12.7 20.8 
 p .000 .000 .129 .120 .000 .046 .261 
Slovenia Mean 54.9 33.3↓ 92.9↑ 84.2 46.0 80.2↓ 37.8↓↑ 
 SD 29.5 32.6 8.9 13.2 18.7 12.5 20.7 
 p .212 .000 .010 .612 .968 .018 .016 
Switzerland Mean 52.3 56.9 94.1 84.7 59.8↑ 87.3 41.5 
 SD 38.9 28.1 9.9 15.2 23.4 11.5 23.7 
 p .567 .159 .128 .625 .010 .570 .303 
Total Mean 47.4 68.8 87.7 82.7 45.8 85.5 47.5 
 SD 33.0 33.5 16.9 16.3 20.9 12.1 21.8 
Mean practice scores (%) per country and across countries with standardized variation. Scores significantly 
deviating from the mean of all countries are marked, with p values displayed. 
1  SBP below threshold: SBP<140 mmHg 
2  DBP below threshold: DBP<90 mmHg 
3  LDL below threshold: LDL<2.5 mmol/l 
 
Practice size 
In the analyses per country practice size did not consistently correlate to the 
outcomes (data not shown). In Slovenia 4 of the 12 outcomes (recording of 
physical activity capacity and BMI or weight, advice or contraindication for physical 
activity, influenza vaccination) had a significant positive association with practice 
size; 7 outcomes were non-significant positive and one was non-significant 
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negative. We found one other significant association: In England practice size and 
the indicator score related to influenza vaccination were negatively associated. 
For the outcome measure recording of physical activity capacity all countries 
showed a positive association, though significant only in Slovenia. 
Across all 8 countries we found no association between practice size and indicator 
scores. In countries with a strong primary care system practice size was positively 
associated with the score on influenza vaccination (OR 1.28, 95%CI 1.01–1.61) 
and negatively with the LDL cholesterol level score (OR 0.86, 95%CI 0.74–0.99). 
In countries with a weak primary care system we could not detect associations 
between practice size and outcomes. 
We assessed the relative contribution of practices and countries to the variance in 
indicator scores, the ICC scores (see Table 4). Of the indicator scores on SBP, 
DBP and LDL about 10% of the variance could be explained at the practice and 
country level together. In all other indicators more of the variance could be 
explained, about 15-30% at the practice level and up to 18% at the country level. 
 
Table 4.  Intra Class Coefficients 
 
Indicator Country level Practice level 
Smoke status recorded  11.6  31.7 
Physical activity capacity recorded  0.9  29.1 
Weight or BMI recorded  7.6  24.7 
Blood pressure recorded  16.4  28.4 
Cholesterol recorded  17.0  19.3 
Advice or contraindication for physical activity  2.1  28.6 
Influenza vaccination  18.2  17.9 
Antiplatelet therapy  6.1  26.1 
Statin advised or prescribed  2.5  15.2 
SBP below threshold  3.4  7.9 
DBP below threshold  3.8  7.4 
LDL below threshold  3.6  6.5 
 
Discussion 
This is, to our knowledge, the first large scale study on CVRM in European primary 
care at a larger scale. We found that scores on quality indicators in general vary 
from 45% (a record of advice on physical activity; SBP and LDL below treatment 
targets) up to about 95% (blood pressure recording) of the maximum score, which 
indicates optimal policy. As opposed to our expectation, we found little evidence 
for better performance in large practices. In Slovenia larger practices tended to 
perform better. Our study did not explicitly assess the efficiency of delivering 
CVRM.  
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Similar to our research, the three EUROASPIRE surveys provide data from 
international research with uniform data collection across countries. But in 
EUROASPIRE a specialist care starting point guided CHD patient selection23. 
Raised blood pressure, defined as SBP≥140 mmHg and/or DBP≥90 mmHg or in 
diabetics respectively ≥130 mmHg and ≥80 mmHg, was prevalent in 58-61% of 
these survey samples. Raised cholesterol was defined as ≥4.5 mmol/l and 
diminished from 94.5% in EUROASPIRE I, to 76.7% in the second survey and 
finally to 46.2% in the third. Data collected in the most recent EUROASPIRE 
survey in 2006 and 2007 are comparable to our results. In the Pinnacle program, 
data regarding outpatients from cardiology offices, too, show comparable results 
with for instance antiplatelet and statin therapy in 84.9 and 84.3%, respectively.14 
Previous data on CVRM in primary care can be found in various national studies. 
In a Cochrane review the effects of interventions on the organization of the 
treatment considering ischemic heart disease patients in primary care are 
studied24. Data from the control groups could be considered comparable to our 
audit data. Direct comparable outcomes are statin prescription and antiplatelet 
therapy. In the review 50.1 of the control patients received statin therapy, but 
studies dated back till the 1990's. The most recent study, SPHERE, had with 
80.3% a result comparable to 82.7% in our study. Relating to antiplatelet therapy 
the review result was 72.5% compared to 87.7 in our study sample. Again, the 
more recent data were the best, up to 87.0 In the SHERE study SBP was <140 
mmHg in 66.2% (versus 47.5% in our data) and DBP<90 mmHg in 88.6% of the 
patients (comparable to 85.5% in our data)25. In drug trials efficacy of statins varies 
from 60 to 90% in achieving LDL < 2.5 mmol/l26-29. In our observational study, the 
real life results are on the lower end of this range. In contrast to the optimum 
situation in these drug studies physicians could include every patient known to 
have a CHD, patients without further medical attention, too. The indicator on LDL 
cholesterol treatment target surprisingly was not validated in the Delphi indicator 
development procedure. We can only speculate about the reasons; setting strict 
norms irrespective of the patient’s age might be argued by some or the fact that 
this outcome measure very much depends on the patient in contrast to process 
measures as offering a statin. In view of the strong evidence base for the 
relationship between LDL cholesterol and coronary heart disease we anyhow 
decided to include the LDL cholesterol results in our study. 
Since most patients with increased cardiovascular risk are treated in primary care, 
the findings are extremely relevant for improving care in the different countries 
despite study limitations. They show that specific countries scored high on some 
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indicators and low on others. Improvements in CVRM are possible in all countries. 
Our study allowed to include all patients with a known diagnosis of CHD. 
Inevitably, patients treated in secondary care could be included, too. Our results 
give an overview of the performance of CVRM related to all patients known in the 
primary care practice. 
In England high scores on performance indicators were observed, particularly for 
indicators incentivized as part of the Quality and Outcomes Framework (QOF)30. 
Physicians in England are forced, by their electronic patient records, to tick boxes 
for QOF-indicators, which might be a strong driver for change in registration, 
enhancing good risk factor registration in England. On the other hand, we found 
relatively low performance scores for some indicators of CVRM, especially risk 
factor recording, in the Netherlands. The only indicator related to a financial 
incentive (influenza vaccination) and supported by a national organizational 
program had very high scores in this country (in 2009 a fee of 9.88 euro was 
provided for every vaccinated patient). The system parameter incentives on a 
national level and as such as a country characteristic may have an important 
influence relative to practice size as a practice characteristic. 
The DBP indicator scores were much higher than scores for SBP, though the 
importance of the latter is stressed by its role in risk classification schemes. Advice 
on physical activity had low scores, too, although it remains uncertain whether 
such advice had been provided but not recorded. 
Differences between countries may be partly explained by differences in the 
quality of recording as stated above. Medication and blood pressure or cholesterol 
levels are probably well recorded, but this is less the case for smoking status or 
exercise advice. It might be argued that recorded care does not mirror care 
provided. But in chronic care recording is thought to be essential. Risk factor 
recording is a prerequisite to select patients for treatment and chronic care means 
collaboration between various health care professionals, who will need to rely on 
the data in the patient records31. 
In our study practice size seems to have little relation to performance as measured 
by quality indicators. Though in previous research on practice size no consistent 
results were found, in general larger practices tend to show better performances 
and provide more extensive services, for instance more preventive activities1-5. All 
these studies were based on national data. We took into account the fact that we 
had practices from eight countries by entering country as a level in our multilevel 
analysis. This procedure effected chance on significant findings. Taking into 
account the strength of the primary care did not provide relevant findings. 
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A larger practice offers opportunities to develop skills by experience and gives 
managerial advantages, especially when specialized staff is required. Structured 
care will be more cost effective with larger patient groups included in a program. 
On the other hand, there seems to be a trade of between high quality clinical care 
and interpersonal care, and access might be better in smaller practices2,9. In our 
sample across countries small practices were able to deliver a performance on 
cardiovascular risk management as good as larger practices. 
Only in Slovenia larger practices showed a tendency towards better performance 
in general. We can only speculate regarding this finding. It may be the resultant of 
recent implementation strategies with first effects in larger settings. This would be 
in line with the general concept of larger practices being in a good position for 
providing structured care to larger groups of patients. 
The proportion of variance explained at the practice level was larger than that 
related to the country level, indicating that the practice has more influence on that 
variation than the country. This could stimulate practices to invest in quality 
improvement in their practices as there is little argument that much is determined 
at a higher level out of their reach. A remarkable small part of the variation in 
outcomes is explained at both the practice and the country level considering the 
blood pressure and cholesterol levels. These biological outcomes will be 
determined at the patient level to a greater extend. 
 
Strengths and limitations of the study 
Within the context of our international survey we had to face inclusion bias both at 
the practice level and at the patient level as a result of differences in the 
organization of the health care system within the various countries at different 
levels. Practice selection was random in most countries but a convenience sample 
in two countries (Austria and Switzerland). The procedure for sampling patients, 
too, showed some variation. In Belgium, England, the Netherlands and Slovenia 
patient selection was exclusively based on recorded diagnoses, enabling inclusion 
of patients registered but not controlled in primary care or not at all. Less strict 
methods were used in the other countries (remembering patients, prescription lists, 
attending patients) providing patient inclusion bias. Patients on a prescription list 
by definition have some drug treatment and frequent attenders and treated 
patients are more likely to be remembered. Our practice sample appeared the best 
feasible given the limitations of our international survey. The sample size of 181 
practices forms a limitation to detect small effects of practice size on outcomes, 
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among other due to clustering within countries and differences of possible effects 
between countries. 
Data on practice size were not directly comparable between countries because of 
the differences in health care systems. In some but not all countries patients are 
listed with one GP or practice. Countries without these clear patients' lists had to 
report on numbers of attenders as a measure for practices size. By standardizing 
practice size data per country we solved this potential problem. 
We included patients with CHD to have a patient group more homogeneous than 
the group of CVD patients in general. This did not completely prevent 
heterogeneity within our study population. The CHD group comprised on the one 
hand patients who had a myocardial infarction or vascular surgery and have been 
treated in secondary care and on the other hand patients with stable angina 
pectoris who might have been treated in primary care exclusively. 
 
Conclusions 
The variation between practices within each country is unwanted and proves 
potential for improvement. The presence of highly performing practices within each 
country proves that in each national context good CVRM is possible. Differences 
found between countries and especially best practices can form lessons for all 
countries. For instance the Quality and Outcomes Framework from the UK can be 
an example to other countries but focus may differ according to the national 
situation as the position of primary care within the larger context of the health care 
system. 
In contrast to most previous research our analysis did not indicate significant 
influence of practice size on the quality indicator scores. In various studies larger 
practices tend to perform better, supporting the development of practice 
collaboration with consequently larger groups of CHD patients to organize care. 
This may enhance expertise and logistics. We could not confirm this tendency. 
Here, further research is needed. 
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Abstract 
Objectives: Cardiovascular risk management (CVRM) received by patients shows 
large variation across countries. In this study we explored the aspects of primary 
care organization associated with key components of CVRM in coronary heart 
disease (CHD) patients. 
Design: Observational study. 
Setting: 273 primary care practices in Austria, Belgium, England, Finland, France, 
Germany, The Netherlands, Slovenia, Switzerland and Spain. 
Participants: A random sample of 4563 CHD patients identified by coded 
diagnoses in eight countries, based on prescription lists and while visiting the 
practice in one country each. 
Main outcome measure: We performed an audit in primary care practices in 10 
European countries. We used six indicators to measure key components of 
CVRM: risk factor recording, antiplatelet therapy, influenza vaccination, blood 
pressure levels (systolic <140 and diastolic <90 mm Hg), and low-density 
lipoprotein cholesterol <2.5 mmol/l. Data from structured questionnaires were used 
to construct an overall measure and six domain measures of practice organization 
based on 39 items. Using multilevel regression analyses we explored the effects of 
practice organization on CVRM, controlling for patient characteristics. 
Results: Better overall organization of a primary care practice was associated with 
higher scores on three indicators: risk factor registration (B=0.0307, p<0.0001), 
antiplatelet therapy (OR 1.05, p=0.0245) and influenza vaccination (OR 1.12, 
p<0.0001). Overall practice organization was not found to be related with recorded 
blood pressure or cholesterol levels. Only the organizational domains 'self-
management support' and 'use of clinical information systems' were linked to three 
CVRM indicators. 
Conclusions: A better organization of a primary care practice was associated with 
better scores on process indicators of CVRM in CHD patients, but not on 
intermediate patient outcome measures. Direct support for patients and clinicians 
seemed most influential. 
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Introduction 
Providing high-quality healthcare for patients with chronic diseases poses major 
challenges for healthcare systems. In many countries policy makers aim to 
strengthen the ability of primary care to provide chronic illness care, so that large 
patient populations can be supported reliably over a long period of time. The 
Chronic Care Model (CCM) proposed that six organizational components are 
crucial to achieve this: 'healthcare organization', 'delivery system design', 'decision 
support', 'clinical information systems', 'self-management support', and 'community 
resources and policies'1,2. Box 1 shows a brief description of the six domains. 
Other organizational models, such as the Patient-Centered Medical Home3, 
specified similar components. Although these models are based on some 
research4–10, their positive impact on clinical and preventive performance needs 
further research as implementing best practices for chronic illness management 
shows little success11. While it has been claimed that all organizational 
components are important, it would be informative to get better insight into the 
relative value of different domains. For instance, a study on diabetes care in 17 
centres found that 'delivery system design' was positively correlated to outcomes, 
whereas 'clinical information systems' and 'self-management support' were not 
significantly associated6. 
This paper focuses on cardiovascular risk management (CVRM) in patients with 
coronary heart diseases (CHD) in primary care across Europe. CHD is a condition 
with high morbidity and mortality worldwide12. Practice guidelines with 
recommendations for effective secondary preventive therapy are widely 
available13,14. Although the effects of antiplatelet therapy and of control of blood 
pressure and serum cholesterol levels are beyond discussion, research showed 
that preventive treatment is suboptimal in Europe and the USA15,16. Preventive 
treatment for patients with established CHD is mostly delivered in primary care, 
especially in countries with a strong primary care-oriented healthcare system. 
Substantial variation is observed regarding CVRM received by patients. We expect 
better healthcare organisation to be related to a higher quality of care. The aim of 
our study was to examine which factors of organization of a primary care practice 
are associated with quality of CVRM in CHD patients. 
 
Methods 
This study was part of the EPA Cardio project, an international observational study 
on cardiovascular risk management in 10 European countries17. The participating 
countries comprised a convenience sample: Austria, Belgium, England, Finland, 
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France, Germany, The Netherlands, Slovenia, Switzerland and Spain. In stratified 
samples of primary care practices in each of these countries randomly sampled 
medical records were reviewed to provide data on cardiovascular risk 
management and structured questionnaires among participating general 
practitioners were used to provide data on practice organization. Practices were 
stratified according to urbanization and size sampling based on regional or 
national lists of practices; in Austria and Switzerland a convenience sample was 
included. Patients were included based on coded diagnoses in most countries; in 
Austria prescription lists were used to include patients and in France patients 
visiting the practice were included when eligible. Data collection took place in 
2008–2009. 
 
Indicators for cardiovascular risk management 
Data from medical records were linked to internationally validated indicators on 
cardiovascular risk management, which were developed in a structured Delphi 
procedure18. Primary care physician panels from nine countries initially evaluated 
650 indicators for cardiovascular risk management. This resulted in a core set of 
44 indicators, which were then operationalized in specific measures and tested in 
a pilot study19. This study is based on performance indicators related to preventive 
treatments in CHD patients. Data were obtained from patient medical records. The 
first indicator was an aggregate score which indicated the number of risk factors 
recorded per patient. Risk factors considered were: smoking behaviour, body 
mass index, physical activity, blood pressure, and cholesterol levels (range 0-5). 
Five other indicators, all dichotomous, were: a record of antiplatelet therapy unless 
contraindicated, influenza vaccination offered, systolic blood pressure <140 
mmHg, diastolic blood pressure <90 mmHg, and low-density lipoprotein (LDL) 
cholesterol <2.5 mmol/l. 
 
Organization of primary practice  
A large set of questions on practice organization was included in structured 
questionnaires, which were partly administered in written form and partly in 
interviews with the general practitioner in the participating practices who was the 
research participating contact person. These questions mainly comprised items 
from the European Practice Assessment (EPA) instrument. This EPA instrument 
was previously validated in an international project20. We constructed post hoc 
measures by linking items to one of the six domains of the Chronic Care Model as 
published before21. All items were formulated positively, with 'yes' indicating the 
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presence of a characteristic. We dichotomized all answers as either 'yes' or 'no', 
the latter consisting of 'no', 'missing value', or 'not applicable'. The aggregated 
scores of the following five CCM domains were positively correlated: 'healthcare 
organization' (7 items), 'delivery system design' (15 items), 'decision support' 
(3 items), 'clinical information systems' (6 items) and 'self-management support' 
(4 items). These correlations were highly significant with Spearman’s rho values 
varying from 0.2 to over 0.6. For that reason, an overall measure of structured 
chronic care was defined with a scale from 0 to 5, with equal weight for each CCM 
domain. Factor analysis showed a Cronbach's α of 0.74. One CCM domain, 
'community resources and policies' (4 items), was left out of the overall score due 
to difference in focus and lower correlation with other domains. 
 
Data analysis 
In order to examine the associations between practice organization and 
performance indicators we applied multilevel regression analyses, using indicators 
for cardiovascular risk management as outcomes. Age and gender were included 
as explanatory variables (covariates) at the patient level. The second level was the 
practice level at which the organizational measures were specified. On this level, 
we entered two factors: the domain 'community resources and policies' was a 
predictor in all analyses; furthermore we entered either one of the five other 
domains or the overall aggregated score. The third level was the country level (as 
a fixed factor). The analyses were performed for each of the six outcomes 
separately. The risk factor recording was analyzed in a linear regression model, 
while the dichotomous outcomes, antiplatelet therapy, influenza vaccination, blood 
pressure and cholesterol levels, were handled in binomial logistic regression 
models. We considered p-values of 0.05 or less to indicate statistical significance. 
Patients with a missing value were ignored for that outcome. For the descriptive 
data presentation we used SPSS V.16; the regression analyses were conducted 
using SAS9. 
 
Results 
From the 284 practices in the EPA Cardio study 11 practices were excluded 
because of low numbers of patients. We included 273 primary care practices with 
data on 4563 patients (Table 1). The number of practices varied from 12 in Finland 
to 36 in England and Spain. Overall, one-third of the patients were female; in 
Switzerland and Belgium less than 25%; in Finland and England about 38%. On 
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average patients were over 69 years of age. Patients in Spain were on average 
the eldest: over 73 years of age.  
 
Table 1. Countries, practices and patients included 
 
Country Number of practices Number of patients % female Mean age
Austria 23 307 36.1 71.5
Belgium 23 269 23.6 66.8
England 36 540 38.0 67.9
Finland 12 245 38.4 72.1
France 25 346 27.9 68.5
Germany 26 463 36.9 69.0
Netherlands 35 507 29.1 69.4
Slovenia 35 822 35.8 68.2
Spain 36 722 37.0 73.3
Switzerland 22 342 22.4 67.8
Total 273 4563 33.4 69.5
 
Table 2 presents figures on performance indicators. Overall performance varied 
from 46% of the maximum score for LDL treatment target and 60% for systolic 
treatment target up to 87% for antiplatelet therapy and diastolic treatment target. 
 
Table 2. Indicators for cardiovascular risk management. Percentage of maximum score in risk 
factor recording (with standard deviation) and percentage of the patients with positive 
scores for the binary outcomes is shown (n= 4563 patients with CHD). 
 
 
Risk factor 
recording (SD) 
Anti-platelet 
therapy 
Influenza 
vaccination 
SBP 
<140 mmHg
DBP 
<90 mmHg 
LDL 
< 2.5 mmol/l 
Austria 80.6 (18.6) 86.4 52.8 61.4 85.9 56.1 
Belgium 80.8 (21.2) 90.7 89.2 55.9 85.2 44.8 
England 87.5 (16.6) 92.0 86.7 69.7 95.9 65.5 
Finland 70.1 (24.4) 93.2 72.5 50.2 84.4 65.8 
France 81.4 (16.5) 90.4 59.1 58.9 89.5 38.2 
Germany 80.4 (19.2) 67.5 71.5 58.0 81.3 30.4 
Netherlands 59.8 (31.7) 85.2 96.4 43.6 85.7 45.1 
Slovenia 77.4 (24.8) 93.9 31.8 56.8 79.8 38.2 
Spain 58.1 (32.9) 80.2 67.5 72.8 96.1 45.9 
Switzerland 76.8 (24.2) 95.3 55.2 65.4 87.2 46.3 
Total 74.0 (26.8) 87.0 66.1 60.1 87.1 46.3 
 
Table 3 presents the results of the regression analyses. Overall better practice 
organization was associated with more reliable risk factor registration (B=0.0307, 
p<0.0001), antiplatelet prescribing (OR=1.0533, p=0.0245), and influenza 
vaccination (OR=1.1246, p<0.0001). The same associations were found for the 
component 'clinical information systems'. The component 'self-management 
support' was associated with better risk factor registration (B=0.1676, p<0.0001), 
influenza vaccination (OR 1.55, p=0.0004), and LDL treatment target (OR 1.15, 
p=0.0252).  
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The component 'delivery system design' was associated with better risk factor 
registration (B=0.0352, p=0.0002) and vaccination (OR 1.13, p=0.0036). The 
domains 'health care organization' and 'decision support' were associated with 
influenza vaccination only. The domain 'community resources and policies' was 
found to be associated with diastolic blood pressure < 90 mmHG. 
 
Discussion 
Main results 
A primary care practice with better practice organization showed better 
performance for risk factor registration, antiplatelet prescription and influenza 
vaccination in CHD patients. These findings support the belief that practice 
organization has impact on quality of CVRM in CHD patients across different 
healthcare systems although the observational design does not allow causal 
inferences. 
In table 4, we illustrate the potential impact of the associations found in our study. 
It illustrates that the difference between a poorly organized practice and a well-
organized practice was associated with smaller and larger impact on clinical 
performance. It presents the estimated outcome in a primary care practice with 
every predictor average except for one, varying this predictor from a 10th percentile 
score to a 90th percentile score (to avoid focus on the extremes). With the largest 
difference as a clear example, an average patient in an otherwise average practice 
on the lower end (10th percentile) regarding self-management support has a 50% 
chance of receiving an influenza vaccination as opposed to a patient in a practice 
on the better end of the range (90th percentile) having a 79% chance of receiving 
an influenza vaccination.  
 
Table 4. Estimates of intra class coefficients (ICC), signifying the portion of variance explained by 
country, by practice, or unexplained 
 
 Sum score risk 
factor registration 
Antiplatelet 
therapy 
Influenza 
vaccination
SBD 
<140 mmHg
DBD 
<90 mmHg 
LDL 
<2.5 mmol/l 
ICC countries 0.10433 0.08961 0.23663 0.03026 0.08882 0.05618 
ICC practices 0.25582 0.21132 0.26614 0.06560 0.07269 0.07400 
unexplained 0.63986 0.69908 0.49723 0.90414 0.83849 0.86982 
 
The findings related to 'self-management support' were of particular interest, given 
the current focus on self-management in the health policies of many countries. In 
our study the domain related to having information leaflets available in the practice 
concerning cardiovascular diseases (e.g., CHD, stroke, hypertension, stop 
smoking, etc); presence of a directory of prevention activities/organizations locally 
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available (e.g., gyms, walking group and weight-watchers); offering written 
information on life style regularly; and offering advice about websites for education 
on health risks or healthy life style regularly. It is encouraging that such practical 
items are indeed associated with better clinical processes, although the causality 
remains unknown. 
The organizational domain 'clinical information system' referred to access to 
internet and email in the practice, virus protection, use of a pass word, use of a 
computer-supported patient file system and computer-generated medication 
prescriptions. As data on clinical performance depended on medical records, we 
actually measured to some extent performance and also quality of recording. 
Optimal use of computerized medical record systems leads to better scores for 
practice organization and clinical performance. But as CVRM mainly is a 
collaborative task, healthcare professionals need to be able to rely on the data 
recorded. 
The relevance of a well organized practice mainly concerned preventive 
procedures (risk factor registration, drug prescription and vaccination) rather than 
intermediate outcomes of healthcare (blood pressure and cholesterol levels). 
However, it should be noted that better prescribing of antiplatelet therapy has a 
well-assessed effect on cardiovascular events and mortality22. Likewise, the 
benefits of influenza vaccination in preventing complications are well-documented 
and guidelines recommend vaccination to patients with cardiovascular 
diseases13,14,23. This suggests that better organization of primary care was indeed 
associated with improved survival and fewer cardiovascular events in patients with 
CHD.  
Previous research found associations between practice organization and clinical 
performance4–10,24,25, and a systematic review of trials of organizational 
interventions in CHD patients in primary care found limited evidence for effects on 
outcomes such as blood pressure and serum cholesterol levels26. 
In our explorative analysis of the relevance of various organizational domains, we 
found differential effects on performance. The components ‘self-management 
support’ and ‘clinical information system’ were found to be most consistently 
related to cardiovascular risk management. We cannot rule out the possibility that 
our measures of these domains may have been more accurate than those of other 
domains or that the participating primary care practices had specific characteristics 
explaining the findings. On the contrary, both clinical information system and self-
management are directly linked to decisions and behaviours of clinicians and 
patients, which have known impact on cardiovascular risk. Clinical information 
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systems may be crucial because it is a well-known contribution to the other 
domains. Self-management support is the one domain targeting the patient, 
offering another aspect than the care and practice-related domains. 
The question is how the impact of organization of healthcare on (intermediate) 
patient outcomes can be optimized. Our study may have missed the power to 
detect small effects. Further down the line (system, process and patient 
outcomes), more factors become relevant and influential and to prove the effect of 
care domains subsequently becomes more difficult. 
 
Strengths and weaknesses 
The EPA Cardio study was based on random sampling of patients using well-
developed measures of cardiovascular risk management and practice 
organization, although the measures of the CCM were post hoc constructed. The 
international character of our study contributed to its generalizability and provided 
control for contextual confounders, such as specific reimbursement system or 
national policies. The sampling of countries and practices had limitations with 
respect to representativeness, but provided arguably more generalizable evidence 
than many trials of organizational changes in healthcare. In the patient samples 
women seemed underrepresented. In various national databases male CHD 
prevalence is 1.5–2 times the female prevalence.27–29 Particularly in Belgium and 
Switzerland low numbers of females were included which cannot be accounted for. 
We suggest that the impact of this on our result was limited, because sex and age 
were controlled for in the analyses. 
 
Conclusion 
Our observational study provided data from a real-life situation in contrast with 
many trials of organizational changes in primary care. We found that a better 
organized practice, measured in terms of implementation of the Chronic Care 
Model, had better clinical processes in the targeted cardiovascular domain. Most 
notably, we found that 'clinical information systems' and 'self-management support' 
were relevant. The impact on cardiovascular outcomes was less obvious, which 
may be due to a range of factors. Nevertheless, this study reinforces the 
importance of strengthening the organization of primary care practices for 
improving their clinical performance. 
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Abstract 
Objective: In this study we explored the add on value of community orientated 
programs to enhance healthy life style associated with key components of 
cardiovascular risk management (CVRM) in patients with coronary heart disease. 
Methods: Observational study in Catalonia (Spain), including 36 practices, 
36 professionals and 722 patients with coronary heart disease (37% female: mean 
age 72 (SD 11.73)). Our predictor variable of interest was reported delivery by 
primary care practices (PCPs) of community orientated programs such as physical 
exercise groups and stop smoking, which was collected through structured 
questionnaires administered to professionals of PCPs. Our CVRM outcome 
measures were: recorded risk factors, drug prescription and intermediate patient 
outcomes (blood pressure levels, low-density lipoprotein cholesterol, body mass 
index). 
Results: Thirty practices delivered community programs. Most delivered one [17 
(47.2%) practices] or two programs [11 (30.5%) practices]. The content of these 
programs was orientated to education and motivation to enhance healthy life 
styles, using group counselling sessions, mailed print material and one-to-one 
counselling. In practices delivering community programs more patients received 
anti-hypertensives (89.7%), antiplatelet therapy (80.5%) and statins (70.8%). 
However, none of the differences with the other practices were statistically 
significant. 
Conclusions: No evidence was found for the added value of community orientated 
programs on cardiovascular risk in patients with coronary heart disease, which can 
help clinicians and managers to refine criteria when including patients in 
preventive programs.  
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Introduction 
While progress has been made in reducing mortality, coronary heart disease 
(CHD) still remains one of the main causes of death worldwide1. Evidence based 
recommendations on improving lifestyle (smoking cessation2, physical exercise3, 
diet4 and alcohol5 intake) and drug treatment (statins6-9; antihypertensive 
therapy9,10 and antiplatelet therapy10) have been incorporated as performance 
measures in several health quality frameworks; particularly in primary care, where 
patients with high cardiovascular risk or established cardiovascular disease 
receive preventive treatment11. The management of patients with existing 
cardiovascular disease in the community can be cost-effective, for instance by 
preventing hospital events12. Nonetheless how best deliver and achieve prevention 
targets in this setting is still unclear. Several interventions for enhancing healthy 
life styles in the community have been undertaken, either primary care based13,14 
or by other community providers15, reporting mixed results. The profile of patients 
which can benefit of referral to these interventions is yet to be elucidated. Despite 
so, complementary community interventions to usual care contacts are used in our 
setting to implement preventive activities. In our context, primary care is organized 
as a network of large practices that behave as geographical and administrative 
units and family physicians (from 4 to 36 full time equivalent FPs) are part of the 
staff, together with nurses, paediatricians, social workers, dentists and ancillary 
staff; patients are listed in a practice, FPs are allowed to recall patients and are 
gatekeepers to other care providers16. In Spain, PCPs are responsible to deliver 
the health promotion and preventive activities program (PAPPS)17 developed by 
the Spanish Society of Family Medicine (SemFYC) which integrates the 
international guidelines on cardiovascular prevention. Nonetheless variability exist 
among PCPs on strategies (individual contacts with FPs/nurses and 
complementary community interventions) used to implement preventive activities 
in patients with cardiovascular disease in the community. 
The community approach has been included in theoretical frameworks for quality 
improvement in chronic diseases, such as in the Chronic Care Model (CCM). This 
framework emphasizes that chronic diseases require of an integration of several 
aspects in a health system18 and identifies six essential elements: 'healthcare 
organization', 'delivery system design', 'decision support', 'clinical information 
systems', 'self-management support' and 'community resources and policies'11. 
Evidence reports mixed results on the contribution of each domain to patient 
outcomes. For instance self-management support, clinical information systems 
and decision support have been found to be associated with better outcomes and 
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processes19,20, nonetheless less research has been performed implementing 
community resources elements to judge their relative effectiveness19. Reporting 
evidence on how delivering community interventions for selected patients by PCPs 
relate to their performance can contribute to a better understanding of primary 
healthcare competences and their convergence with primary care management. 
Our aim was to examine whether delivery of community orientated programs to 
enhance healthy life styles was associated to quality of cardiovascular risk 
management (CVRM) in patients with CHD.  
 
Methods 
Study design and participants 
This study was part of the EPA Cardio project, an international observational study 
on cardiovascular risk management conducted in 10 European countries21. Study 
design, participants selection and measures have extensively been described 
previously20,22. Briefly we conducted an exploratory and pragmatic cross-sectional 
study and included a random sample of 36 practices representing rural and urban 
setting (100,000 inhabitants as a cut of point) in Catalonia (Spanish region with a 
population of 7,210,508 inhabitants)23. Each practice provided data for patients 
with prevalent CHD (I20-I25) listed with one of their FPs. Patients with diabetes 
were excluded. Based on a calculation of the statistical accuracy of the estimates 
per each participating country in the EPA Cardio project21, we aimed at least at 15 
patients randomly selected with established CHD per practice. Ethics approval for 
this study was obtained from The Catalan Primary Care Research Institute "IDIAP 
Jordi Gol" ethics committee, over sighted by the Spanish Ministry of Health. 
Our outcome measures were based on European guidelines10 on prevention and 
management of CHD and the validated European Practice Assessment (EPA) 
instrument24, which comprises a list of indicators to measure quality performance 
in primary care. We collected data on prescription of statins, antihypertensive 
therapy and antiplatelet therapy according to the "Anatomical Therapeutic 
Chemical (ATC) Classification System". Patient intermediate outcomes included 
were systolic and diastolic blood pressure, total cholesterol and low-density 
lipoprotein cholesterol (LDL), weight and body mass index (BMI). At patient level 
we also collected information on age, gender, region (rural/urban) and diagnosis of 
hypercholesterolemia (E78) and hypertension (I10) according to the International 
Classification of Diseases Tenth Revision used in primary care. 
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Data described above was provided by PCPs involved in the study, extracted from 
their electronic medical records. None of the officers responsible for data collection 
were involved in the subsequent data analysis. 
As a predictor variable, we selected in a post hoc analysis25, items from the 
validated EPA instrument, to collect information on PCPs participation in 
community programs to enhance healthy life styles. In structured questionnaires 
we asked the research contact person at the practice (FP or nurse practitioner), 
the following questions: (1) Was there a public health project concerning 
cardiovascular risk in your practice the last 2 years? (i.e. physical exercise, stop 
smoking)?, (2) did nurses take part in education about cardiovascular disease risk 
factors (for example, diet, exercise, smoking) in schools?, (3) did GPs take part in 
local/community campaigns or actions on cardiovascular disease risk prevention 
(for example, stop smoking campaigns and fun-runs)?, (4) did nurses take part in 
local/community campaigns or actions on cardiovascular disease risk prevention 
(for example, stop smoking campaigns and fun-runs)?   
We provided descriptive data for age, gender and prevalence of relevant variables 
were calculated for all patients. Chi Square and Student test for categorical and 
continuous variables, respectively were used at bivariate analysis to compare 
patients listed in PCPs with and without delivery of cardiovascular risk reduction 
programs. Question (1) of the structured questionnaire reported us information on 
programs to enhance healthy life styles delivered at the PCPs. Questions (2), (3) 
and (4) reported us descriptive information of professionals involvement in 
community activities related to cardiovascular disease. Multilevel analysis was 
performed establishing PCPs as random units to control the variability associated 
to clinical practice in primary care. Descriptive and bivariate analysis were 
undertaken with the use of SPSS Inc v18 software. Multilevel analysis was 
performed with Stata/IC 11.0. 
 
Results 
Initially we identified 66 potentially eligible PCPs in the urban setting covering a 
population of 558,515 and 37 in the rural setting covering a population of 480,827. 
We randomly included 36 PCP (with 490 FTE GPs), 21 from rural (269.35 FTE 
GPs) and 15 from urban (220.7 FTE GPs) mirroring the situation in our region. 
Each PCP provided a FP as a research contact person.  
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Community  programs to enhance healthy life styles 
Overall about 90% of PCPs usually participate in public health care programs on 
lifestyle and in local/community campaigns or actions on cardiovascular disease 
risk prevention. Participation of nurse practitioners was higher (88.8%) than family 
physicians (66.7%). Thirty (83%) practices delivered community programs to 
enhance healthy life styles. Most practices implemented one [17 (47.2%) 
practices] or two [11 (30.5%) practices] programs at the same time (Table 1). 
These programs were educational programs on risk factors management offered 
in group counselling sessions; mailed print material was also given. Motivation for 
an active lifestyle was promoted through exercise programs consisting of walks 
adapted to recruited patients. These programs were offered by professionals 
working at the PCP, usually nurse practitioners or allied health professionals. Any 
patient from the community listed at the practice could be referred to these 
programs by FPs or nurse practitioners if fulfilling the inclusion criteria.  
 
Table 1. Description of programs to enhance healthy life styles 
 
Name of intervention Goal 
 
Type of intervention Practices  
(n=36) 
Patients
(n=722) 
High Blood Pressure 
reduction program 
education/ motivation to 
reduce blood pressure 
group counselling sessions; 
mailed print 
8 (22.2%) 159 
Obesity reduction program education/ motivation to 
reduce weight 
group counselling sessions; 
mailed print 
2 (5.6%) 30 
Exercise promotion program education/ motivation to 
an active lifestyle 
group counselling sessions; 
mailed print 
22 (61.1%) 435 
Diet education program education/ motivation to 
change diet habits.  
group counselling sessions; 
mailed print 
4 (11.1%) 118 
Smoking cessation program education/ motivation to 
stop smoking 
one-to-one counselling / 
group counselling sessions; 
mailed print 
9 (25%) 218 
 
Cardiovascular risk management provided to patients  
We collected data from 722 patients listed at the participating PCPs, 282 from rural 
setting and 440 from urban. PCPs from urban setting delivered significantly 
(P<0.001 ) more programs to enhance healthy life styles than rural areas (Table 
2). Mean age for our sample was 72 years (SD 12) with 50.7% of patients ≥ 60 
years and 37% women (Table 2). Overall patients listed in PCPs delivering 
programs to enhance healthy life styles did not significantly differ from those 
without in age, gender and prevalence of hypercholesterolemia, smoking and 
hypertension. In the overall sample, drug prescription was high for anti-
hypertensive therapy (88.9%), antiplatelet therapy (80.2%) and lower for statins 
(69.5%).  
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Table 2.  Patient characteristics  
 
 n=722 patients, n=36 practices 
Age (Mean, SD) 72 (12) 
Gender (female, %) 267 (37) 
Smoking n (%) 54 (7.5) 
Men over 60 years old (%) 366 (50.7) 
Hypercholesterolemia (%) 230 (31.9) 
High Blood Pressure (%) 442 (61.2) 
Patients from Urban/Rural setting 440 (60.9) / 282 (39.1)* 
Systolic Blood Pressure (Mean, SD) 131.09 (16.14) 
Diastolic Blood Pressure (Mean, SD) 72.56 (10.05) 
Total Cholesterol (Mean, SD) 182.69 (36.51) 
LDL (Mean, SD) 104.04 (28.64) 
Weight (Mean, SD in Kg) 74.06 (14.47) 
BMI (Mean, SD ) 28.38 (4.6) 
Prescription of statins (%) 502 (69.5) 
Anti-hypertensive therapy (%) 642 (88.9) 
Antiplatelet therapy (%) 579 (80.2) 
*Primary care practices from urban setting significantly (P<0.001) implement more risk reduction programs. 
 
In practices delivering programs to enhance healthy life styles patients received 
more anti-hypertensive therapy (89.7%), antiplatelet therapy (80.5%) and statins 
(70.8%) versus the other practices (Table 3); nonetheless the bivariate analysis 
showed no significant differences neither for drug prescription, risk factors 
registration and intermediate patient outcomes. Differences were found for 
prescriptions of statins, but after adjusting for random differences between PCPs 
this effect was no longer significant. Registration of BMI was low in both groups. 
 
Table 3.  Management of patients listed in practices with and without delivery of programs to 
enhance healthy life styles 
 
 Delivery of programs to enhance healthy life styles
 
WITH 
n=650 patients 
n=30 practices 
WITHOUT 
n=72 patients 
n=6 practices P value  
Risk factors registration    
BP  484 (74.5) 58 (80.6) P=0.31 
Total col. n (%) 394 (60.6) 48 (66.7) P=0.37 
BMI n (%) 212 (32.6) 27 (37.5) P=0.43 
Risk factors management    
Systolic Blood Pressure mmHg (Mean, SD) 130.77 (15.77) 133.81 (18.99) P=0.18 
Diastolic Blood Pressure mmHg (Mean, SD) 72.64 (9.85) 71.93 (11.62) P=0.61 
Total Cholesterol mg/dl (Mean, SD) 183.20 (37.18) 178.52 (30.59) P=0.40 
LDL (Mean, SD) 104.28 (29.48) 102.29 (21.98) P=0.67 
Weight Kg (Mean, SD) 73.79 (14.32) 76.40 (15.72) P=0.33 
BMI (Mean, SD ) 28.33 (4.61) 28.80 (4.74) P=0.62 
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 Delivery of programs to enhance healthy life styles
 
WITH 
n=650 patients 
n=30 practices 
WITHOUT 
n=72 patients 
n=6 practices P value  
Risk factors control 
Blood pressure: % patients with BPSYS and 
BPDIAS < 140/90 mmHg 352 (54.2) 37 (51.4) P=0.71 
BMI: % patients with BMI <25kg/m2 45 (6.9) 4 (5.6) P=0.81 
% patients with total cholesterol < 175mg/dl 170 (26.2) 20 (27.8) P=0.78 
LDL: % patients with LDL<100mg/dl 151 (23.2) 19 (26.4) P=0.56 
Drug prescription    
Statins (%) 460 (70.8) 42 (58.3) P=0.04* 
Anti-hypertensive therapy (%) 583 (89.7) 59 (81.9) P=0.07 
Antiplatelet therapy (%) 523 (80.5) 56 (77.8) P=0.64 
*Multilevel analysis showed no significant difference on statins prescription (p=0.084) 
 
Discussion 
In our sample of primary care practices the delivery of community orientated 
programs to enhance healthy life styles was not associated to better 
cardiovascular risk management in patients with CHD, although prescription of 
preventive medication tended to be better.  
The implementation of the six components of The Chronic Care Model has been 
emphasized to achieve high-quality healthcare for patients with chronic diseases 
in a health system, because of the supporting synergistic effects; nonetheless 
advantages to implement multiple components rather than single have yet to be 
elucidated19. Self-management support, clinical information systems and decision 
support have been found to be associated with better outcomes and processes in 
the literature19,20. On the other hand, less research has focused on the linkage with 
community resources for people with chronic illness. Our results seemed to 
suggest that the linkage with community resources did not relate with quality of 
clinical process and outcomes in patients with CHD. This may be related to the 
wide implementation of most of the CCM elements25 in Spain. There might have 
been little room for added value of community programs for enhancing healthy life 
styles at least in patients with established cardiovascular disease, who probably 
received a relatively high amount of support and counselling.  
Community programs for enhancing healthy life styles in community primary care 
has not been uniformly successful26. For instance in Europe, two primary care-
based community interventions aimed at lifestyle improvement to patients at 
cardiovascular risk found opposite results. A Dutch study13 reported no effects on 
determinants of behavioural change. On the other hand, positive effects 
(decreased body weight, waist and hip circumference, body mass index, waist–hip 
ratio, systolic and diastolic blood pressure, triglycerides, and glycosylated 
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haemoglobin) were found in a Swedish trial14. In an Australian study, no clear 
benefits were seen on blood lipids, diet or body mass from patients at 
cardiovascular risk participating in an intensive program requiring a heavy time 
commitment from nurse counsellors relative to routine care provided by interested 
family physicians27. On the other hand, in United States, a community health 
worker-based program was successful on reducing 10-year CHD risk and 
improvements in dietary patterns, weight, blood pressure and cholesterol levels15.  
This variability of findings in the literature could be explained by a range of factors, 
including patient selection, targeted population, type of intervention (individual or 
group counselling, health policies ...), service provider (primary care based or 
other community providers), and to the quality of the intervention itself (i.e. the 
quality of the counselling techniques used, targeted barriers, professionals' skills 
…). Several barriers to success on lifestyle behavioural changes have been 
associated to either primary care professionals such as lack of time, costs, patient 
compliance, lack of counselling skills28,29 and to patients such as dissatisfaction 
with the quality of counselling received by those working in primary care30; lack of 
skills, lack of will power, reluctance to change culturally rooted behaviours31 and 
strong sense of fatalism regarding the course of their disease in terms of that no 
action would guarantee protection31,32. 
The role that family physicians have in achieving benefits to patients at 
cardiovascular risk can be crucial27. There is some evidence that the behaviour of 
primary health care providers in offering lifestyle advise can be increased through 
a range of strategies33. On the other hand, evidence also suggests that specialized 
community-based providers outside primary care settings can overcome patients’ 
barriers focusing on enhancing education of patients and improving quality of care 
and health outcomes by also addressing community-level factors hindering the 
adoption of healthy behaviours15,34. 
In our Spanish environment, previous experiences show that when it fits with a 
national target or a research agenda, primary care practices are capable to deliver 
successful public health programs. For instance the ISTAPS smoking cessation 
program involved 176 PCPs across Spain in a 6 month intervention which 
consisted in implementing recommendations from an evidence-based clinical 
practice guideline on smoking cessation to targeted patients achieving positive 
results in patient outcomes. Nonetheless the patients’ profile who benefit from this 
intervention were younger (mean age 42 years) and without comorbidities 
compared to patients in our study. Our structural organisation of primary care 
allows population based prevention at community level. Despite so, resources 
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constraints may require to refine criteria to include patients in preventive programs 
or re-adapt these programs according to selected patients. On the other hand, 
when compared with international literature our professionals perform in the 
average. For instance, high levels of control for systolic and diastolic blood 
pressure when comparing to other European countries have been reported; but 
our level of risk factors registration was one of the lowest20. 
The best way to deliver prevention in the community is still unclear, and further 
research is required, particularly on cost-effectiveness. Despite which provider is 
responsible for delivering care at community level, evidence suggest that the role 
that motivated family physicians could have on changing patients behaviours plus 
addressing individual as well as community-level elements are key factors to 
consider, which may suggest that care needs to be seen as a continuum to 
achieve effective interventions. 
The limitations of our study design, patient selection and measures may have an 
effect on our results. Particularly the lack of power of our sample due to the low 
variability of the predictor variable. The wide implementation of community 
programs at PCPs level, may be responsible for the fact that the trends we found 
did not reach significance, for instance the positive trends identified in prescription 
of preventive medicines in those practices delivering programs to enhance healthy 
life styles. We could not have access to detailed information of these programs 
delivered by PCPs such as inclusion criteria, quality of the counselling provided 
and patient attendance rate. Nevertheless we did not aim at evaluating 
effectiveness of these programs, rather we intended to examine the add on value 
of community interventions in quality CVRM in patients with an established 
cardiovascular disease. 
 
Conclusions 
The delivery of community orientated programs for enhancing healthy life styles by 
primary care was not associated with better cardiovascular risk management in 
patients with coronary heart disease. This can help service management to refine 
criteria when including patients in preventive programs.   
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Abstract 
Introduction and objectives: Scarce research has been performed in ambulatory 
patients with chronic heart failure in the Mediterranean area. Our aim was to 
describe survival trends in our target population and the impact of prognostic 
factors. 
Methods: We carried out a population-based retrospective cohort study in 
Catalonia (north-east Spain) of 5659 ambulatory patients (60% women; mean age 
77 [10] years) with incident chronic heart failure. Eligible patients were selected 
from the electronic patient records of primary care practices from 2005 and were 
followed-up until 2007. 
Results: During the follow-up period deaths occurred in 950 patients (16.8%). 
Survival after the onset of chronic heart failure at 1, 2, and 3 years was 90%, 80%, 
69%, respectively. No significant differences in survival were found between men 
and women (P=.13). Cox proportional hazard modelling confirmed an increased 
risk of death with older age (hazard ratio=1.06; 95% confidence interval, 1.06-
1.07), diabetes mellitus (hazard ratio=1.53; 95% confidence interval, 1.33-1.76), 
chronic kidney disease (hazard ratio=1.73; 95% confidence interval, 1.45-2.05), 
and ischemic heart disease (hazard ratio=1.18; 95% confidence interval, 1.02-
1.36). Hypertension (hazard ratio=0.73; 95% confidence interval, 0.64-0.84) had a 
protective effect. 
Conclusions: Service planning and prevention programs should take into 
consideration the relatively high survival rates found in our area and the effect of 
prognostic factors that can help to identify high risk patients. 
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Introduction 
The prevalence of chronic heart failure (CHF) in developed countries is between 
1% and 3% and increases with age1–4. The management of CHF represents an 
important economic burden for healthcare systems and accounts for 1% to 2% of 
the total health care expenditure5,6. 
CHF is also lethal, particularly after onset7,8, and worsens after hospital 
admission9–11. Other factors such as age, sex and comorbidities have been 
described to be determinants of prognosis12. The interaction among these factors 
is complex13 and complicates management particularly in primary care where 
diagnosis is often initiated14 and patients are followed-up. However, little research 
has been performed in ambulatory patients managed in the community15. Most 
studies performed to date have been clinical trials or studies that included patients 
after hospital discharge7. Moreover, little is known on specific trends and 
prognostic factors for community CHF cohorts in the Mediterranean area; a lower 
incidence16 and lower risk of fatal coronary heart disease have been described17,18 
even though cardiovascular risk factors are similar to those found in the rest of 
Europe19. In Spain, trends in survival are mainly reported by the national data 
registry from hospital-based heart failure clinics20 and large community population-
based studies representing the Mediterranean lifestyle are lacking. 
The aim of this study was to document longitudinal survival trends in ambulatory 
patients with CHF in Catalonia (north-east Spain) and to assess the impact of 
comorbidity and hospitalization on survival.a 
 
Methods 
Study design and setting 
We designed a population-based retrospective cohort study using the resources of 
a project published in clinical trials database (NCT00792402), which evaluated the 
impact of a computerized clinical guideline on CHF in Catalonia (population of 
7,210,50821). Briefly, in this project, a pragmatic, nonequivalent, controlled, before-
and-after quasi-experimental study was performed using a population-based 
approach. Patients from 2 regions (urban and rural) were included. This project 
was established to evaluate a complex intervention in the urban setting where 
primary care practices (PCPs) were randomized. Half the PCPs followed usual 
care management plus a computerized clinical guideline on CHF and half 
underwent a disease management intervention. 
                                                     
a It should say: 'the impact of comobordity on survival.' 
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For the purpose of this study, data from both regions were combined. Despite 
urbanization differences, both regions shared the same organizational features22 
(Table 1). Ethical approval for this study was obtained from the Health Care Ethics 
Committee of the Institut d'Investigació en Atenció Primària Jordi Gol. 
 
Table 1.  Organizational features of participating primary care practices 
 
Features Urban region/Rural region 
Health care provider Catalan Health Service for 80% of the population in the autonomous community of 
Catalonia (population of 7,210,508). This health care provider belongs to the 
Spanish National Health System 
Coverage Universal coverage for both primary and secondary care 
Funding State funded through general taxes. Co-existence with the private sector 
Access to care All citizens are registered with a family physician who acts as a gatekeeper to 
specialized care 
Medical records Electronic patient records system 
Provision of care Network of practices that behave as a geographical and administrative units where 
physicians are part of the staff (from 4 to 36 physicians per practice depending on 
the population attended) 
Single health care centresa. Single health care centres and satellite officesb. 
Diagnosis process / 
Integrated care 
Cardiologists and other specialized services attending practices weekly since 1990 
to support physicians on the diagnosis process, management and training 
a applies only to urban region 
b applies ontly to rural region 
 
Participants 
We included incident patients attending PCPs from 2005 to 2007. Patients aged 
more than 30 years old with a diagnostic code related to CHF, registered by their 
primary care physician (I11.0, I13.0, I13.2, I50, I50.0, I50.1, I50.9, P29.0, 
according to the International Classification of Diseases Tenth Revision used in 
primary care) were included. As a measure of diagnostic accuracy we only 
included patients prescribed diuretics. In the urban region, we included the 
randomized set of PCPs that followed usual care plus clinical practice guideline on 
CHF and excluded those PCPs that underwent the disease management 
intervention. We included all PCPs in the rural region. 
 
Measures 
We measured survival after the onset of CHF until death or the end of follow-up 
(31 December 2007). Onset of CHF referred to the recorded date of diagnosis of 
CHF, which we extracted from the primary care electronic patient records. 
Registration of the diagnosis was done by primary care physicians and in our 
context is usually done after cardiologist consultation or advice (Table 1) or after 
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the patient has been admitted to hospital. As a measure of the accuracy of the 
diagnosis, we only included patients prescribed diuretics. We also measured 
survival in patients with hospital admission for cardiovascular causes during the 
follow-up, as a primary discharge diagnosis (398-398.99, 402-402.91, 428-428.9, 
997.1, 403.90-403.91, 404-404.93, 411-411.89, 414-414.9 according to the 
International Classification of Diseases Ninth Revision used by hospitals). We 
included mortality from any cause. 
Potential comorbidities associated with survival were defined on the basis of the 
International Classification of Diseases Tenth Revision codes registered in the 
primary care electronic patient records either before or at the onset of CHF and 
were chosen according to a review of the literature, clinical relevance, and 
availability. We included patient age and sex, hypercholesterolemia, hypertension, 
diabetes mellitus, ischemic heart disease, chronic obstructive pulmonary disease, 
and chronic kidney disease (Table 2). We obtained age by calculating the 
difference between the date of inclusion in our study (1 January 2005) and date of 
birth and considered 2 categories: patients aged less than 65 years and patients 
aged 65 years or older. Setting was also considered as a covariate. 
 
Table 2. International Classification of Diseases Tenth Revision Codes related to comorbidity 
included in this study 
 
Hypercholesterolemia (E78) 
Hypertension (O10-O10.4; O11, O13, O14, O16; I10, I11, I11.9, I12, I12.0, I12.9; I13, I13.1, 
I13.9; I15-I15.2, I15.8, I15.9) 
Diabetes Mellitus (E10-E10.9; E11-E11.9; E12-E12.9; E13-E13.9;E14-E14.9;P70.2;N08.3; O24-
O24.4, O24.9). 
Ischemic Heart Disease (I20-I20.1; I20.8, I20.9; I21-I21.4, I21.9, I21.11; I22-I22.1, I22.8; I23-I23.6, I23.8; 
I24.1, I24.8, I24.9; I25-I25.6, I25.8; I40-I40.1, I40.8, I40.9; I41-I41.2, I41.8; I42-
I42.9; I43-I43.2, I43.8; I51-I51.9; I52-I52.1, I52.8). 
Chronic kidney disease (N13.2; N15.8; N16, N16.0, N16.2-N16.4; N17-N17.2, N17.8, N17.9; N18, N18.0, 
N18.8, N18.9;N19; N20.1; N02.3-N02.5; N07-N07.9; O90.4; Q27.1, Q27.2; 
Q61.4; P96.0; N25, N25.0; N14.1-N14.4; N15-N15.1, N15.9;I70.1; I72.2; M10.3; 
A98.5; Y84.1; R39.2; I82.3; Z99.2; K76.7). 
Chronic Obstructive 
Pulmonary Disease 
(J43-J43.2, J43.8, J43.9; J44-J44.1, J44.8, J44.9; J47). 
 
Data Sources 
From January 2005 to December 2007, we extracted data from 3 national 
database sources, which we were able to match because every Catalan citizen 
has a unique and anonymous identification number for health care use. The 
central database of the Catalan Health Service facilitated data abstraction from the 
electronic patient records of PCPs. Data from hospital admissions was gathered 
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from the Division of Demand and Activity Registries (Minimum Basic Data Set for 
Acute-care Hospitals) of the Catalan Health Service, where all Catalan hospitals 
are required to send in their data for reimbursement. Information on mortality was 
gathered from the Mortality Register of Catalonia, where fatalities had to be 
notified. We recorded as fatality cases patients codified as such in the primary 
care electronic patient records register and those also identified in the Mortality 
Register of Catalonia. 
None of the officers responsible for data abstraction were involved in the 
subsequent data analysis. 
 
Statistical Methods 
Descriptive data from our sample on age, sex and comorbidities are presented. 
We calculated the entire cohort follow-up period and reported the median, 
minimum and maximum values. Candidate variables significantly associated with 
mortality in the bivariate analysis (P<.05) were included as potential covariates in 
the multivariable model. In the bivariate model, the chi square text and Fisher's 
exact test were used for categorical variables and Student's t test for continuous 
variables. Kaplan Meier analysis was used to determine long-term survival. The 
Cox proportional hazards model was used to examine the independent effect of 
candidate variables. The forward and backward step technique with the likelihood 
ratio test was used. Discrimination of the model was calculated with Harrell's C-
index, and calibration of the model was calculated with the Gronnesby and Borgan 
test. Constant hazard was tested with the log (-log S[x]) vs Log(time) graphic. All 
tests were 2-tailed and significance was set at the 5% level (a=0.05). Missing 
values were calculated (0.2% of our final sample) and were found not relevant in 
our analysis. 
The statistical analysis was performed with SPSS v18 software and StataCorp12. 
 
Results 
Initially we identified 13,008 potentially eligible patients with a diagnosis of CHF 
from 43 PCPs, covering a population of 1,039,342 listed citizens. 
We excluded 2221 patients without registration of the date of diagnosis and 5128 
patients with a prevalent diagnosis of CHF or without a prescription for diuretics. 
Our final sample consisted of 5659 patients from 43 PCPs: 3641 (64.3%) from 
urban areas (covering a population of 558,515 inhabitants) and 2018 (35.7%) from 
rural settings (covering a population of 480,827 inhabitants). The median follow-up 
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period of the entire cohort was 3 years with a minimum of 0.08 years and a 
maximum of 3 years.  
Patient characteristic in the sample did not differ substantially from those of the 
initial population (Table 3). The mean (standard deviation) age of our sample was 
77 (10) years; 88.3% of the patients were aged 65 years or more and 60% were 
women. During the study period, 585 patients (10.3%) were hospitalized for 
cardiovascular causes. The median interval after the onset of CHF was 1.6 years. 
Regarding comorbidities, the bivariate analysis showed that in those patients who 
died during the follow-up, hypertension was more prevalent in women (P=.022) 
and in patients aged 65 years or more (P=.029), while chronic obstructive 
pulmonary disease (P<.001), ischemic heart disease (P<.001), and chronic kidney 
disease (P=.009) were more common in men. Diabetes mellitus was more 
frequent in patients aged less than 65 years (P=.041), while hypercholesterolemia 
was also more frequent, although this difference was not statistically significant 
(P=.771). 
 
Table 3. Patient characteristics 
 
 Study sample (n=5659) Population (n=13,008) 
Age, years 77 ± 10 (available for 5654) 76 ± 11 (available for 12,963) 
Age < 65 656 (11.6) 1793 (13.8) 
Age ≥ 65 4998 (88.3) 11170 (85.9) 
Women  3402 (60) 7671 (59) 
Hospitalization during follow up  585 (10.3) 1233 (9.5) 
Time after the onset of CHF, years  1.6 (1.0, 2.2)  2.21 (1.23, 3.57) [available for 10,787 
patients]  
Patients on diuretics  5659 (100) 9391 (72.2) 
Patients on ACE inhibitors/ARB 4537 (80.2) 9262 (71.2) 
Patients on beta-blockers 2086 (36.9) 4137 (31.8) 
Hypercholesterolemia  444 (7.8) 1206 (9.3) 
Hypertension  3996 (70.6) 9134 (70.2) 
Diabetes Mellitus  1686 (29.8) 4105 (31.6) 
Ischemic heart disease  1458 (25.8) 3540 (27.2) 
CKD  624 (11.0) 2044 (15.7) 
COPD  827 (14.6) 2060 (15.8) 
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers; CHF, chronic heart failure; CKD, 
chronic kidney disease; COPD, chronic obstructive pulmonary disease. 
Data are expressed as no. (%), mean ± standard deviation or median [interquartile range]. 
 
During the follow-up period, 950 patients died (16.8%).  
Survival after the first, second and third year of follow-up was 90%, 80%, 69%, 
respectively (Figure); no significant differences (P=.13) in survival were found 
between men and women.  
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Cox proportional hazard modelling (Table 4) confirmed an increased risk of death 
for older age (hazard ratio [HR]=1.06; 95% confidence interval [95%CI], 1.06-
1.07), diabetes mellitus (HR=1.53; 95%CI, 1.33-1.76), chronic kidney disease 
(HR=1.73; 95%CI, 1.45-2.05), and ischemic heart disease (HR=1.18; 95%CI, 1.02-
1.36). Hypertension (HR=0.73; 95%CI, 0.64-0.84) had a protective effect. We did 
not find a significant effect according to the setting. 
 
Figure.  Overall survival in incident patients during the follow-up period. No statistically significant 
differences 
 
 
 
 
Patients at risk 
Men  1982  1131  342 
Women  2988  1731  526 
 
The assumption of constant hazard was met. The discrimination of the model was 
0.67. 
Calibration of the model (P=.03) was significant for the first decile only and was not 
significant for the remaining deciles, indicating that the model failed in patients with 
lower risk. 
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Table 4. Multivariable model reporting the effect of prognostic factors on survival (n=5647), Cox 
Proportional Hazards Model  
 
 HR (95% CI) 
Age, years 1.06 (1.06-1.07) 
Diagnosis of chronic kidney disease 1.73 (1.45- 2.05) 
Diagnosis of diabetes mellitus 1.53 (1.33-1.76) 
Diagnosis of ischemic heart disease 1.18 (1.02-1.36) 
Diagnosis of hypertension 0.73 (0.64-0.84) 
95%CI, 95% confidence interval; HR, hazard ratio 
 
Discussion 
In our study 90% of ambulatory patients with CHF survived 1 year after onset. 
Independent predictors of a worse outcome were older age, diabetes mellitus, 
chronic kidney disease, and ischemic heart disease. In contrast with previous 
studies carried out in hospital-based cohorts or selected patients from clinical 
trials, we evaluated mortality trends and predictors of mortality for ambulatory 
patients in a Mediterranean community-based cohort. 
Comparisons with other studies are hampered by differences in patient selection, 
patient characteristics, and follow-up periods. Nevertheless, our survival rates 
were higher than those reported in the literature, such as the Framingham8 (57% 
for men and 64% for women) and Rochester23 (77%) studies in the United States, 
and the Hillington7 (62%) study in the United Kingdom. All of these studies 
reported incident CHF. In our study, survival was also higher than that in a study in 
the Netherlands24 (74% survival at 1 year), which used a selection process similar 
to ours. In prevalent CHF, studies in central Europe reported a 1-year survival rate 
of 87.4%25 and 89%26. 
On the other hand, our survival rates for incident CHF were in line with those 
reported by the Spanish national data registry from hospital-based heart failure 
clinics20 (survival rates at 1 and 2 years of 90% and 80%, respectively). Higher 
mortality (about 30% mortality at 1 year) was found in the south of Spain27, 
although this phenomenon has been described as a paradox28, as this mortality is 
the highest in Spain and is associated with ischemic heart disease mortality, 
illiteracy, and unemployment29. In contrast, we found a low rate of 
hypercholesterolemia and ischemic heart disease in our cohort, which could partly 
explain our positive results on survival. None of the above studies analyzed the 
effect of comorbidities on outcomes. 
Our results show that Mediterranean countries may also have better outcomes for 
CHF in addition to the favorable trends reported in coronary heart disease17,18. It 
has been hypothesized that regional factors30, as well as the implementation of 
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evidence-based therapies and risk factor management19, may confer protection. At 
the organizational level, there may be differences in the role played by primary 
care in health care systems on risk factor control and in fast tracking to specialist 
care. To allow comparisons, these issues should be further investigated in 
epidemiological studies in other Mediterranean countries. 
Despite differences in patient selection and patient characteristics, the predictors 
of worse prognosis in our study were similar to those found in previous community-
based studies. There is common agreement on the effect of older age both in the 
United States and Europe, although disparities exist regarding sex and other 
prognostic factors. Although we found no effect of sex on survival, several studies 
have reported better survival in women8,24,25. Other factors that increase the risk of 
death are diabetes mellitus8,26,31, hospitalization25 and renal failure7,23,25,26. 
Hypertension has been previously reported23 as a positive predictor for survival. In 
a multivariable analysis, we found better survival among patients with a diagnosis 
of hypertension registered in their electronic medical records. The higher survival 
was probably due to the negative effect of low systolic blood pressure on 
prognosis described elsewhere7,25,26 rather than to the diagnosis of hypertension 
itself, which is one of the causes of diastolic heart failure and is more prevalent in 
women and older patients, who usually have a longstanding history of 
hypertension24,32,33. 
 
Limitations 
Our study has some potential design limitations concerning the inclusion of 
participants and measures. Although we did not have access to the set of PCPs 
excluded in the urban region, we found no significant differences among the 
regions included in this study. We expected that any other ethnic or 
socioeconomic effect on outcomes would have been minimized by our selection 
process, which developed from a previous randomization performed for a 
concomitant disease management intervention. 
We identified CHF patients through their primary care physician's electronic patient 
records but did not know how many of them had undergone echocardiography and 
therefore lacked information on the etiology of CHF, which would have aided 
interpretation of our results. As a measure of diagnostic accuracy, we only 
selected patients who had been prescribed diuretics to perform our data analysis 
and possibly missed patients with CHF not receiving diuretics. 
Usually, in our setting, primary care physicians register the diagnosis of CHF after 
confirmation by a specialist. This specialist is also involved in the diagnostic 
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process and management of these patients in the community and provides 
support to primary care physicians in their setting, as this has been part of our 
integrated care program since 199034 (Table 1). Although we could not exclude the 
possibility that diagnosis of CHF was made clinically by the primary care physician 
alone in some cases, our results on survival were consistent with those found in 
the Spanish national data registry. 
Our predictive model had a modest predictive power (c=0.67) and also low 
goodness-of-fit (P=.03), particularly for the first decile, with higher goodness-of-fit 
for the remaining deciles, indicating that the model failed in patients at lower risk. 
These results could be explained by 2 reasons: a) comorbidities were identified 
through the primary care physicians' registration in electronic patient records and 
we were unable to capture how long patients had been exposed to the conditions 
or to obtain information on severity by using biomarkers, and b) the sample size 
was large (over 500 cases in each decile), increasing the possibility that every 
small difference would be significant. Nonetheless, our model was clinically 
relevant and in line with reports in the literature. 
Because of the low registration on New York Heart Association classification and 
left ventricular ejection fraction, we could not present survival data according to 
these factors. Such information would have provided more detailed information on 
the severity of CHF. Primary care physicians do not usually record this information, 
nor do they do so as open access text, which also hampered access. 
Finally, we considered the date of registration of CHF in the primary care 
physicians' electronic medical records, which did not necessary reflect the date 
when the diagnosis was made, although our survival rates matched those in 
national database registers. 
 
Conclusions 
Survival rates in our community cohort of patients with CHF were relatively high. 
Clinicians and managers need to consider this favorable prognosis in service 
planning, as well as the effect of prognostic factors, which could help to identify 
high-risk patients. 
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Abstract 
Objectives: Little is known on predictors of hospitalization in ambulatory patients 
with chronic heart failure, and known predictors may not apply to Mediterranean 
countries. Our aim was to document longitudinal trends in hospitalizations and 
identify patient-related predictors of hospital admission, re-admission and length of 
stay in the targeted population. 
Methods: Population-based retrospective cohort study in Catalonia (North-East 
Spain), including 7196 ambulatory patients (58.6% women; mean age 76 years). 
Eligible patients were selected from the electronic patient records of primary care 
practices, and followed for 3 years. 
Results: At 3 years of follow up overall 645 (9.0%) patients had cardiovascular 
hospitalization, 37% were readmitted, and median length of stay was 9 
(interquartile range 5-17) days. Chronic kidney disease [odds ratio (OR)=1.98 
(1.62-2.43)], IHD [OR=1.72 (1.45-2.04)], DM [OR=1.50 (1.27-1.78)] and chronic 
obstructive pulmonary disease [OR=1.43 (1.16-1.77)] increased the risk for 
hospitalization. DM [OR=1.70 (1.22-2.38)], IHD [OR=1.85 (1.33-2.58)] and HTA 
[OR=1.66 (1.11-2.46)] increased the risk for readmissions. Chronic kidney disease 
[OR of 2.21 (1.70-2.90)], IHD [OR of 2.19 (1.73-2.77)], DM [OR= 1.70 (1.34-2.15)], 
HTA [OR=1.51 (1.13-2.01)], chronic obstructive pulmonary disease [OR=1.37 
(1.02-1.83)] increased the risk for long length of stay in hospital. 
Conclusions: Our study identified predictors of hospitalization, readmissions and 
long length of stay which can help clinicians and managers to identify high risk 
patients which should be targeted on service planning and when designing 
preventive actions. 
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Introduction 
Hospitalizations for chronic heart failure (CHF) have major impact on patient's 
quality of life and imply high costs for societies'. In many industrialized countries 
management of CHF represents 1-2% of total healthcare expenditure and up to 
two-third of this cost is in relation with hospitalizations1-4. Although recent reports 
suggest that CHF has probably reached its peak, it remains a highly prevalent 
cause of hospitalization5,6. CHF accounts for 5% of acute hospital admissions and 
rises in patients older than 65 years7,8. Despite so, there is a surprising lack of 
epidemiological prospective studies identifying potential prognostic predictors6. A 
better insight into these predictors may help to identify patients with increased risk 
at an early stage for preventive actions. 
CHF is a condition mostly managed in primary care9,10. Family physicians (FPs) 
play an important role in the early and accurate initial diagnosis, risk factors 
identification and disease monitoring11. But this is a complex condition with 
patients who are often elderly and frail, with comorbidity and polypharmacy12. This 
complexity is not always represented in clinical trials; thus, research with "real 
world patients" registered in primary care would be applicable to their everyday 
practice. Factors such as age, gender, diabetes, respiratory disease and renal 
failure have been associated by several studies to hospitalization13,14, 
readmissions15 and length of stay5,16,17. Nevertheless. These studies are mainly 
hospital based, and epidemiological studies with ambulatory patients are 
scarce6,13. In addition, in Mediterranean countries, cardiovascular patients tend to 
have better outcomes than similar patients in other countries, so predictors of 
hospitalization may be different as well. 
In Spain, Health Care System is strongly primary carebased18 acting as a first point 
of contact for patients and as a gatekeeper to specialist care. On the other side, it 
has a strong interface with specialist care. Nevertheless, hospitalization trends are 
mainly reported from National Hospital database registry8 and clinical trials19 and 
large prospective community-population based studies reporting on readmission, 
length of stay and prognostic factors are lacking. The aim of this study was to 
document longitudinal trends in hospitalizations and identify patient-related 
predictors of hospital admissions, re-admissions and length of stay among 
ambulatory CHF patients in Catalonia (north-eastern Spain). 
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Participants and methods 
Study design and setting 
We performed a population-based retrospective cohort study using the resources 
of a project published in Clinical Trials database (NCT00792402). Briefly, this 
project used a non-equivalent controlled, before and after, quasi-experimental 
design with a population based approach to evaluate the impact of a clinical 
practice guideline on CHF in Catalonia (population of 7,210,508)20. Primary care 
practices (PCPs) from urban (intervention group) and rural (control group) setting 
were included. PCPs of the intervention group were randomized and half were 
exposed to usual care plus a clinical practice guideline on CHF and the other half 
to a disease management intervention (which did not participate in our project). 
For the purpose of this study, data from both regions were combined. Despite 
urbanization differences, both regions shared same organizational features21 
(Table 1). The ethics committee of the Catalan Primary Care Research Institute 
"IDIAP Jordi Gol", overseen by the Spanish Ministry of Health approved this study. 
 
Table 1.  Organizational features of participating primary care practices 
 
Features Urban region/rural region  
Health care provider "Catalan Health Institute" care provider for the 80% of the population in the 
Autonomous Community of Catalonia (population of 7,210,508). Belongs to the 
Spanish National Health System 
Coverage Universal coverage for both primary and secondary care 
Funding State funded through general taxes. Co-existence with private sector 
Access to care Every citizen is registered with a family physician who acts as a gatekeeper to 
specialized care 
Medical records Electronic patient records system 
Provision of care Network of practices that behave as geographical and administrative units where 
physicians are part of the staff (from 4 to 36 physicians per practice depending on 
population attended) 
Single health care centresa  Single health care centres and satellite officesb 
Diagnosis process / 
Integrated care 
Cardiologists and other specialized services attending practices weekly since 1990 
to support physicians on the diagnosis process, management and training 
a applies to urban region 
b applies to rural region 
 
Participants 
We selected patients from PCPs and followed them for 3 years, from January 
2005 to December 2007. PCPs of the rural area were all included. In the urban 
area we included those PCPs exposed to usual care plus a clinical practice 
guideline on CHF and excluded the rest of PCPs exposed to a disease 
management intervention which was not targeted by our project as described 
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above. At patient level, we included patients over 30 years old attending PCPs, 
with a diagnosis of CHF (I11.0, I13.0, I13.2, I50, I50.0, I50.0 I50.1, I50.9, P29.0 
according to the International Classification of Diseases Tenth Revision used in 
primary care) registered by their FP during the period of our study (incident cases). 
 
Measures 
Our primary measures were hospitalization, readmissions, length of stay and long 
length of stay. We defined hospitalization as any cardiovascular admission 
between 2005 and 2007 as primary diagnosis at discharge (398-39899, 402-
40291, 428-4289, 9971, 40390-40391, 404-40493, 411-41189, 414-4149 
according to the International Classification of Diseases Ninth Revision used by 
hospitals); re-admissions as more than one cardiovascular admission between 
2005 and 2007, length of stay as total number of days spent in hospital per year 
and long length of stay as days above the median spent in hospital over the follow 
up period. Potential comorbidity associated to primary measures were included 
according to the review of the literature, clinical relevance and availability and 
were defined on the basis of the International Classification of Diseases Tenth 
Revision codes registered in the primary care electronic patient records (Table 2).  
 
Table 2. ICD10 Codes related to comorbidity included 
 
Hypercholesterolemia (E78) 
Hypertension (O10-O10.4; O11, O13, O14, O16; I10, I11, I11.9, I12, I12.0, I12.9; I13, I13.1, 
I13.9; I15-I15.2, I15.8, I15.9). 
Diabetes Mellitus (E10-E10.9; E11-E11.9; E12-E12.9; E13-E13.9;E14-E14.9;P70.2;N08.3; O24-
O24.4, O24.9). 
Ischemic Heart Disease (I20-I20.1; I20.8, I20.9; I21-I21.4, I21.9, I21.11; I22-I22.1, I22.8; I23-I23.6, I23.8; 
I24.1, I24.8, I24.9; I25-I25.6, I25.8; I40-I40.1, I40.8, I40.9; I41-I41.2, I41.8; I42-
I42.9; I43-I43.2, I43.8; I51-I51.9; I52-I52.1, I52.8). 
Chronic kidney disease     
- CKD- 
 (N13.2; N15.8; N16, N16.0, N16.2-N16.4; N17-N17.2, N17.8, N17.9; N18, 
N18.0, N18.8, N18.9;N19; N20.1; N02.3-N02.5; N07-N07.9; O90.4; Q27.1, 
Q27.2; Q61.4; P96.0; N25, N25.0; N14.1-N14.4; N15-N15.1, N15.9;I70.1; I72.2; 
M10.3; A98.5; Y84.1; R39.2; I82.3; Z99.2; K76.7). 
Chronic Obstructive 
Pulmonary Disease           
-COPD- 
(J43-J43.2, J43.8, J43.9; J44-J44.1, J44.8, J44.9; J47). 
 
 
We included hypercholesterolemia (HCL), arterial hypertension (HTA), diabetes 
mellitus (DM), ischaemic heart disease (IHD), chronic obstructive pulmonary 
disease (COPD), and chronic kidney disease (CKD). We also included age and 
gender. We obtained age by calculating the difference of initial date of our study 
(1 January 2005) and date of birth and considered two categories such as less 
than 65 and ≥ 65 years old. Also we considered region and time since onset of 
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CHF as covariate variables. Time since onset of CHF was calculated as the time 
(years) from date of diagnosis registration in primary care electronic clinical 
records to the final date of our study (31 December 2007) or dead. Mortality from 
any cause was included. Diagnosis of CHF was made after hospital confirmation, 
cardiologist advice or echocardiography (Table 1). We also collected patients on 
diuretics, angiotensin-converting enzyme, angiotensin II receptor blockers and 
beta-blockers. 
 
Data sources 
We obtained primary care information from the central database of 'Catalan Health 
Institute', by one of their informatics officer with access to electronic patient 
records. Data from hospital admissions were collected from the Division of 
Demand and Activity Registries (Minimum Basic Data Set for Acute-care 
Hospitals-MBDS), of the Catalan Health Service, where Catalan hospitals are 
committed to send in their data for reimbursement. Information on mortality was 
abstracted from the Mortality Register of Catalonia where fatalities must be notified 
and added to the information held by primary care electronic patient records on 
patient status. We were able to link all the information from the three database 
sources because every Catalan citizen has a unique and anonymous identification 
number for health care use. The informatics officers responsible for data 
abstraction were not involved in the subsequent data analysis. 
 
Statistical methods 
Descriptive data for age, gender and comorbidities are presented for all patients. 
For categorical variables frequencies were reported. For continuous variables, 
mean and standard deviation (SD) were calculated. Median and interquartile range 
(IQR) were calculated for the variables time since onset of CHF and length of 
hospital stay. Candidate variables (measures) significantly (p < 0.05) associated 
with primary measures in the bivariate analysis were included as potential 
covariates in logistic regression models. Chi-Square and Student-Fisher test for 
categorical and continuous variables, respectively, were used at bivariate analysis. 
Forward step technique with likelihood ratio test was used. Multivariate adjusted 
odds ratios and accompanying 95% confidence intervals were calculated. 
Discrimination of the model was assessed by the area under the receiver 
operating characteristic (ROC) curve. Hosmer and Lemershow goodness of fit test 
was used for calibration of the model. All tests were 2-tailed and significant at 5% 
level (alpha = 0.05). Multivariable analyses were performed considering all 
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patients and also excluding fatalities. All analyses were undertaken with use of 
SPSS Inc v18 software. 
 
Results 
Study population 
We initially identified 20,576 potentially eligible patients with the diagnosis of CHF 
from 68 PCPs, covering a population of 1,522,564 listed citizens. According to our 
inclusion criteria we excluded 25 PCPs from the urban setting and 5812 patients 
with prevalent CHF. Our final sample was 7196 patients with incident CHF from 43 
PCPs: 4750 from urban (covering 558,515 inhabitants) and 2446 from rural 
(covering 480,827 inhabitants). The median follow up for the entire cohort was 
1095 days with a minimum of 31 and a maximum of 1095 days. Patients' 
characteristics are presented in Table 3. In the bivariate analysis, we found that 
HTA was significantly more prevalent in patient's ≥ 65 years and women while 
CKD, COPD and IHD were more prevalent in men. HCL, HTA, CKD, IHD and 
COPD were significantly (p < 0.001) more prevalent in the urban setting than in the 
rural although. No significant differences were found according to age, sex and 
DM. 
 
Table 3. Patients' characteristics  
 
 All (n=7196) 
Age (available for 7173). Mean (SD). 76 (10) 
Age < 65 n (%) 973 (13.5) 
Age ≥ 65 n (%) 6200 (86.2) 
Sex –women n (%) 4214 (58.6) 
Cardiovascular admissions during the follow up  n (%) 645 (9.0) 
Patients on diuretics n (%) 5659 (78.6) 
Patients on ACE / ARB n (%) 5539 (77) 
Patients on beta blockers n (%) 1638 (22.8) 
Hypercholesterolemia n (%) 644 (8.9) 
Hypertension n (%) 5061 (70.3) 
Diabetes Mellitus n (%) 2184 (30.4) 
IschemichHeart Disease n (%) 1941 (27.0) 
CKD n (%)  925 (12.9) 
COPD n (%) 1067 (14.8) 
n, number of patients; SD, Standard deviation; ACE, angiotensin-converting enzyme; ARB, Angiotensin II 
receptor blockers; CKD, Chronic Kidney Disease; COPD, Chronic Obstructive Pulmonary Disease. 
 
Hospitalization trends 
In three years of follow up overall 645 (9.0%) patients had an admission to hospital 
due to cardiovascular reasons. Along the follow up period the number of 
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hospitalizations decreased from 435 in 2005 to 153 in 2007 (Table 4). Multivariate 
modelling identified four predictors of hospitalization at three years of follow up 
(Table 5). CKD was the strongest predictor of hospitalization (OR=1.98; 95% 
confidence interval [95%CI] 1.62-2.43), followed by IHD with (OR=1.72; 95%CI 
1.45-2.04), DM (OR=1.50; 95%CI 1.27-1.78) and COPD (OR=1.43; 95%CI 1.16-
1.77). For this explanatory model the area under the ROC curve was 0.627, and 
the maximum difference between observed and predicted hospitalization was 2%. 
 
Table 4. Hospitalization, readmission and length of stay trends over the follow up 
 
 2005 2006 2007 Follow up period (2005-2007) 
n=7196 
Patients alive, n 7196 7143 6688 6055 
Deceased patients, n 53 455 623 1131 
Patients admitted to hospital, n 435 194 153 645 
> 1 admission,n (%) 99 (22.8) 54 (27.8) 44 (28.8) 238 (37.0) 
Length of stay (days), median (IQR: 
P25-P75). 
8 (5-15) 7 (3-14) 8 (4-13) 9 (IQR 5-17) 
n, – number of patients. IQR, InterQuartile Range: Percentile 25, Percentile 75. 
 
Table 5. Multivariable models 
 
Variables Hospitalizations 
n=7196 
Re-admissions 
n=7196 
Long length of stay 
n=7196 
 OR 95% CI OR 95% CI OR 95% CI 
Diabetes Mellitus 1.50 1.27-1.78 1.70 1.22-2.38 1.70 1.34-2.15 
Ischemic Heart Disease 1.72 1.45-2.04 1.85 1.33-2.58 2.19 1.73 - 2.77 
CKD  1.98 1.62-2.43 a a 2.21 1.70 - 2.90 
COPD  1.43 1.16-1.77 a a 1.37 1.02-1.83 
REGION (URBAN) a a a a 1.63 1.23 - 2.14 
Diagnosis of Hypertension a a 1.66 1.11-2.46 1.51 1.13-2.01 
a  No association was found. CKD, Chronic Kidney Disease. COPD, Chronic Obstructive Pulmonary 
Disease. 
 
Re-admissions 
Among the 645 patients with any hospitalization due to cardiovascular reasons 
along the follow up period, 37% were readmitted. Percentage of readmissions 
increased from 22.8% in 2005 to 28.8% in 2007 (Table 4). Range of admissions 
for the follow up period was 1-9. After three years of follow up, multivariate 
modelling identified three predictors for readmissions (Table 5): DM (OR=1.70; 
95%CI 1.22-2.38), IHD (OR=1.85; 95%CI 1.33-2.58) and HTA (OR=1.66; 95%CI 
1.11-2.46). For this explanatory model the area under the ROC curve was 0.633. 
For this model the maximum difference between observed and predicted re-
admission was 14.5%. 
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Length of stay 
Median length of stay per patient in hospital after the follow up period was nine 
days (IQR 5.17) (Table 4). Multivariate modelling for the whole follow up period 
(Table 5) identified five predictors for long length of stay (>9 days): CKD 
(OR=2.21; 95%CI 1.70-2.90), IHD (OR=2.19; 95%CI 1.73-2.77), DM (OR=1.70; 
95%CI 1.34-2.15), HTA (OR=1.51; 95%CI 1.13-2.01) and COPD (OR=1.37; 
95%CI 1.02-1.83). Patients from urban region were associated to longer length of 
stay (OR=1.63; 95%CI 1.23-2.14). For this explanatory model the area under the 
ROC curve was 0.675 and the maximum difference between observed and 
predicted long length of stay was 0.68%. Multivariable models did not provide 
substantially different results when excluding fatalities from the analysis, except for 
readmissions (ROC curve of 0.643) and long length of stay (ROC curve of 0.688), 
which became more discriminative. 
 
Discussion 
In our cohort of ambulatory patients with CHF only 9.0% of patients were admitted 
to hospital due to cardiovascular reasons during three years of follow up. During 
that period we found that while the number of admissions and length of stay 
decreased, the number of readmissions increased. We also provided a risk profile 
for each of our main measures, hospitalization, readmission and long length of 
stay in hospital, according to comorbidities that were found to be associated to 
increase such risk. We found that despite we had a low prevalence of IHD (27%), 
this still was associated with an increased risk of hospital events. In contrast with 
previous studies, that were done in hospital-based cohorts or selected patients 
from clinical trials, we evaluated trends and predictors of hospitalization, 
readmission and length of stay for ambulatory patients in a Mediterranean 
community-based cohort. 
 
Hospitalizations 
No previous data from a community perspective confirmed the decrease on 
hospitalization trends found also in national hospital surveys either from United 
States13, North5 or Central Europe22. Our admission rates due to cardiovascular 
reasons were lower compared to those previously reported from the United 
States23 or United Kingdom24. Reasons for that may remain in the organization of 
provision of care. We have a strong primary care management of chronic 
conditions in the community, with specialists supporting FPs and home care that 
could explain this result. Our risk profile for admissions was in line with what is 
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reported by hospital-based studies13,14. Also Dunlay et al.23 from a community 
perspective found DM and creatinine clearance as predictors for CHF 
hospitalization. 
 
Readmissions 
Little is known on studies analyzing high-risk profile for readmissions due to CHF 
from a wide pool of patients from primary care. Most of the studies are hospital-
based or have used government administrative data25. Despite that these results 
do not bring a unique risk model for readmissions which to compare to, we 
confirmed the effect of DM and IHD similarly to what some of them reported26. 
Despite our hospitalization rate being low, we found a high readmission rate, 
increasing over the period of our study. A similar finding has also been reported in 
hospital-based studies5,15. A reason for that may be that management of CHF in 
the community may delay patient hospitalization up to a more severe stage when 
hospitalizations are more frequent. 
 
Length of stay 
Understanding which patients managed in the community are at higher risk to 
increase their stay in hospital can be an aid to clinicians and managers on health 
care planning nevertheless this is yet to be elucidated. In our cohort, comorbidities 
associated to increase the risk to stay longer time than the median in hospital were 
CKD, IHD, DM, HTA and COPD. We observed a decrease over time in the median 
of length of stay in hospital as reported by hospital-based studies5,16. 
 
Limitations of the study 
We did not capture admissions to private hospitals or outside of targeted setting. 
However, we included listed patients of PCPs with a hospital assigned. These 
patients rarely would go to private hospital or attend other PCPs or public hospital 
because of our continuum of care model. Data from the Catalan government show 
that about 90% of patients use their assigned hospital27. We were not able to 
report on the New York Heart Association classification and the Left Ventricular 
Ejection Fraction that would provide clinically important information on the severity 
and type of CHF and might have clarified the effect of an earlier onset of CHF on 
hospitalizations and our higher readmission rates. We identified CHF patients 
through their FPs' electronic patient records and could not have access to the 
number and echocardiography results performed in each patient. However, in our 
setting, usually FPs register a CHF diagnosis or any other comorbidity diagnosis 
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after specialist confirmation, who is involved in the diagnosis process and 
management of these patients in the community, providing support to FPs in their 
setting, as this is part of our integrated care program since 199028 (Table 1). As a 
measure of accuracy of the diagnosis we reported a high percentage of patients 
on diuretics. We did not analyze variability between FPs; nonetheless, our 
objective was to report trends of hospitalization for the CHF disease rather than 
primary care professional's performance. Anyway, all FPs participating in this 
study belonged to the same primary care provider and had the same electronic 
patient record system, which makes easily available all the International 
Classification of Diseases Tenth Revision diagnosis codes when the FPs need to 
record a diagnosis. We did not analyze separately hospitalizations due to CHF or 
other cardiovascular conditions that could have provided more clinical information 
about the physiopathology of the CHF. In addition, we used the date of CHF onset 
registered by FPs which do not necessarily reflect the date when the diagnosis 
was made. The exclusion of some PCPs in the urban region may explain 
differences in hospitalization trends found in the two settings analyzed. 
Nonetheless, we expected that any other ethnic or socioeconomic effect on 
outcomes would have been minimized by our selection process that started off 
from a previous randomization done by a concomitant disease management 
intervention in the former setting. 
 
Conclusions 
Our study identified predictors of hospitalization, readmissions and long length of 
stay which can help clinicians and managers to identify high risk patients which 
should be targeted on service planning and when designing preventive actions. 
Nevertheless, future research should study more in depth how severity of 
associated comorbidity can have an effect on hospital events for CHF patients and 
so modify their risk profile. 
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Abstract 
Background: Multimorbidity and polypharmacy pose challenges to improving the 
quality of care.  
Objectives: To determine the association between prescription of recommended 
treatment in ambulatory patients with chronic heart failure and multiple 
comorbidities and hospitalization events. 
Design A population-based retrospective cohort study in Catalonia (north-east 
Spain). 
Participants: We included 7173 newly registered patients with chronic heart failure 
(59% women; mean [SD] age 76.3 [10.7] years). Patients were selected from the 
electronic patient records of primary care practices and followed for three years. 
Outcome measures: Prescription of angiotensin-converting enzyme inhibitors 
(ACEI), angiotensin II receptor blockers (ARBs) and beta-blockers (BB). 
Results: Prescription of ACEI/ARBs in patients managed in primary care without a 
hospitalization event during the follow-up rose from 50.8 to 83.5% for 0 and ≥ 4 
comorbidities, respectively, and for ACEI/ARBs and BB from 13.1 to 30.6% for 0 
and ≥ 4 comorbidities respectively. Patients with a hospitalization event were 
treated more often (ACEI/ARBs or 1.47 [1.17-1.85]; ACEI/ARBs and BB or 1.41 
[1.17-1.69]). Comorbid conditions receiving more treatment were hypertension 
(ACEI/ARBs, or 3.75 [3.33-4.22]; ACEI/ARBs and BB or 1.40 [1.23-1.59]), diabetes 
mellitus (ACEI/ARBs or 1.79 [1.57-2.04]; ACEI/ARBs and BB or 1.33 [1.18-1.49]) 
and ischaemic heart disease (ACEI/ARBs or 1.25 [1.10-1.42]; ACEI/ARBs and BB 
or 3.01 [2.68-3.38]). 
Conclusion: Prescription of recommended treatment in patients with chronic heart 
failure increased as the number of comorbidities increased. Family physicians can 
provide equivalent care to more complex patients and those less complex, 
according to the number of comorbidities. 
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Introduction 
Chronic heart failure (CHF) is a prevalent and costly condition. In many 
industrialised countries, costs represent between 1 and 2% of total healthcare 
expenditure, and up to two thirds of costs are related to hospitalizations1,2. 
Because the prevalence of CHF increases with age and the elderly population is 
growing it is expected to be a heavier burden in future3,4. Appropriate treatment of 
heart failure effectively improves survival and quality of life5. International 
guidelines recommend widespread use of both angiotensin-converting enzyme 
inhibitors (ACEI) and beta-blockers (BB) to improve symptoms and survival unless 
a specific contraindication exists6,7. Despite these recommendations treatment of 
patients with CHF remains suboptimal8,9. 
CHF is mostly managed in primary care, where the diagnosis is often initiated8,10 
and the condition followed up. Several studies using qualitative methods have 
reported that the complexity of these patients, because of ageing, comorbidities 
and uncertainty about diagnosis, are self-reported by family physicians (FPs) to be 
barriers to the use of recommended treatments11,12. Whether this is consistent with 
FPs' real clinical performance has not yet been reported in large community 
studies. Previous trials showed that specialist care increases the probability of 
receiving the recommended treatment for CHF when compared with usual care by 
FPs, but the complexity of these patients in terms of comorbidities was not 
considered13,14. The aim of this study was to determine the association between 
prescription of recommended treatments in ambulatory patients with CHF and 
concomitant comorbidities, with or without hospitalization events, in Catalonia 
(north-east Spain). 
 
Methods 
Study design and setting 
We conducted a population-based retrospective cohort study using the data 
collected in a project published in the Clinical Trials database (NCT00792402). 
Briefly, this project used a non-equivalent controlled before and after quasi-
experimental design with a population-based approach to evaluate the impact of a 
clinical practice guideline on CHF in two regions of Catalonia (a Spanish region 
with a population of 7,210,508)15. For this study, we combined data from both 
arms, including intervention (urban) and control (rural) regions. Despite 
urbanization differences, both regions shared the same organizational features 
(Table 1).16 
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Participants 
We selected patients newly registered with a diagnosis of CHF (codes I11.0, I13.0, 
I13.2, I50, I50.0, I50.0 I50.1, I50.9 and P29.0 according to the International 
Classification of Diseases Tenth Revision used in primary care) during the study 
follow-up (January 2005 to December 2007). Registration of the diagnosis was 
done by FPs using electronic patient records. We included patients over 30 years 
old because we did not have younger patients fulfilling the inclusion criteria. We 
only included patients with information recorded in their electronic patient records 
for all measures that we analyzed. At practice level, we included all primary care 
practices (PCPs) in the rural area. In the urban area, we included just those PCPs 
participating in the project described above (half of all the PCPs in the urban area), 
which were selected from a previous randomisation process. 
 
Measures 
Our primary measures were patients with a prescription of ACEI or ARBs; or 
alternatively ACEI or ARBs with BB if a diagnosis of asthma was not present. We 
collected this information at the end of each year of the follow-up period. Our 
primary predictors were the total number of conditions affecting each patient and 
recorded hospital events due to cardiovascular causes. We selected those 
comorbidities recorded in the primary care electronic patient record associated 
with worsening CHF prognosis17. We defined these on the basis of the 
International Classification of Diseases Tenth Revision codes used in our primary 
care setting including hypercholesterolemia, hypertension, diabetes mellitus, 
ischaemic heart disease, chronic obstructive pulmonary disease (COPD) and 
chronic kidney disease (CKD) codes recorded either before or during the period of 
our study. We considered any hospital events due to cardiovascular causes as a 
primary diagnosis at discharge during the period of follow-up (codes 398–39899, 
402–40291, 428–4289, 9971, 40390–40391, 404–40493, 411–41189, 414–4149 
and V173 according to the International Classification of Diseases Ninth Revision 
used in hospital databases). Other covariates considered were patient age, gender 
and region. We obtained age by calculating the difference between the initial date 
of our study (1 January 2005) and date of birth. CHF diagnosis was recorded by 
FPs, which in Catalonia is usually done after consultation with a cardiologist 
(Table 1) or after hospital admission, although the source of the diagnosis was not 
registered in the electronic patient record. We also collected patients with diuretics 
prescription in each group. We also considered mortality from any cause. 
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Table 1.  Organizational features of participating primary care practices 
 
Features   
Health care provider Catalan Health Institute care provider for the 80% of the population in the 
Autonomous Community of Catalonia (population of 7,210,508) and belongs to the 
Spanish National Health System 
Coverage Universal coverage for either primary and secondary care 
Funding State funded through general taxes. Coexistence with private sector 
Access to care Every citizen is registered with a family physician who acts as a gatekeeper to 
specialized care 
Medical records Electronic patient records system 
Provision of care Network of practices that behave as geographical and administrative units in which 
physicians are part of the staff (from 4 to 36 physicians per practice depending on 
population attended) 
Single health care centres (urban regions); Single health care centres and satellite 
offices (rural regions) 
Diagnosis process / 
Integrated care 
Cardiologists and other specialized services attending practices weekly since 1990,
to support physicians on the diagnosis process, management and training 
 
Data sources 
The central database of the Catalan Health Institute supplied us with all patient 
information required for this study, as recorded by FPs in electronic patient 
records. Patient information related to hospital admissions was collected from the 
Division of Demand and Activity Registries (Minimum Basic Data Set for Acute 
Care Hospitals; MBDS), of the Catalan Health Service, where Catalan hospitals 
are committed to send in their data for reimbursement. Information on mortality 
was provided by the Mortality Register of Catalonia and we combined this 
information with the FPs mortality register on patient status. We were able to link 
all data from the three database sources because every Catalan citizen has a 
unique and anonymous identification number for health care use. The informatics 
officers responsible for data abstraction did not participate in the subsequent data 
analysis. 
 
Statistical methods 
Descriptive data for age, gender and prevalence of relevant variables were 
calculated for all patients and according to hospitalization events. Chi-square and 
Pearson tests, for categorical and continuous variables, respectively, were used to 
conduct bivariate analysis comparing patients with and without a hospitalization 
event. The probability of the total number of comorbidities and hospitalization 
events associated with primary measures (ACEI/ARBs, ACEI/ARBs and BB) was 
reported using multivariable and multilevel logistic regression models. For this 
purpose, we merged the six comorbidities included in our study into four 
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categories (one, two, three and four or more comorbidities) to increase the power 
of the analysis because some of the categories did not have enough patients; we 
considered this variable as categorical. Primary measures were converted into two 
dichotomous variables for the whole follow-up period (prescription of ACEI or 
ARBs at any time during the follow-up; or ACEI/ARBs and BB at any time during 
the follow-up). 
Because patients were selected from PCPs, we established those as random units 
to control for the variability associated with primary care clinical practice. Next, we 
established a conditional basal model with the covariates region and 
hospitalization. Using a step-forward method we introduced each candidate 
variable (the number of comorbidities and hospitalization) into the basal model and 
compared the two models using the likelihood ratio test. The final multivariate 
regression model included the basal model together with the significant candidate 
variables. All tests were two-tailed and significant at 5% level (α = 0.05). Patients 
with missing values for any of the relevant variables were excluded from the 
analysis. We also calculated the probability of each comorbidity receiving 
treatment. All analyses included all patients (including deceased) and those who 
survived the study period; we did not find significant differences in prescriptions. 
Missing values were calculated (0.3% of our final sample) and found to be not 
relevant for the results of our analysis. 
All analyses were undertaken with use of StataCorp. 2009 (Stata Statistical 
Software: Release 11, StataCorp LP, College Station, TX, USA). 
 
Results 
Initially, we identified 20,576 potentially eligible patients with a diagnosis of CHF 
from 68 PCPs, covering a population of 1,522,564 listed citizens. According to our 
sampling and inclusion criteria, we did not study cases from 25 urban PCPs, and 
we excluded patients diagnosed before our study period (3591), those with an 
unknown diagnosis registration date (2221), and 23 patients for whom there was 
no information on the relevant variables. Our final sample included 4735 patients 
from urban areas (covering 558,515 inhabitants) and 2438 patients from rural 
areas (covering 480,827 inhabitants). 
Patient characteristics and comparison according to hospitalization event are 
presented in Table 2. Overall, patients without hospital events had a lower 
prevalence of comorbidities. The group with hospital events during the follow-up 
period had significantly more patients on diuretics (P < 0.001), ACEI/ARBs (P < 
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0.001) and ACEI/ARBs and BB (P < 0.001). We did not find significant differences 
related to age and gender. 
 
Table 2. Patients' characteristics  
 
 Overall 
n=7173 
No hospital event
n=6528 
Hospital event 
n=645 
P value 
(Pearson)
Age (Mean, SD) 76.5 (10.5) 76.5 (10.5) 77.1 (10.4) 0.134 
Gender [n (%) women] 4202 (58.6) 3835 (58.7) 367 (56.9) 0.193 
Hypercholesterolemia n(%) 675 (9.4) 614 (9.4) 61 (9.5) 0.944 
High blood pressure n(%) 5129 (71.5) 4646 (71.2) 483 (74.9) 0.049 
Diabetes Mellitus n(%) 2275 (31.7) 2010 (30.8) 265 (41.1) <0.001 
Ischemic heart disease n(%) 2023 (28.2) 1757 (26.9) 266 (41.2) <0.001 
CKD n(%)  1132 (15.8) 972 (14.9) 160 (24.8) <0.001 
COPD n(%) 1136 (15.8) 1004 (15.4) 132 (20.5) 0.001 
Rural region n(%) 2438 (34) 2247 (34.4) 191 (29.6) 0.007 
Urban region n(%) 4735 (66) 4281 (65.6) 454 (70.4) 0.007 
Patients on diuretics n(%) 5654 (78.8) 5069 (77.6) 585(90.7) <0.001 
ACE/ARBs in 2005-2007 n(%) 5533 (77.1) 4990 (76.4) 543 (84.2) <0.001 
ACE/ARBs + BB in 2005-2007 n(%) 1635 (22.8) 1438 (22) 197 (30.5) <0.001 
Comorbidities per patient. Median (IQR) 2 (1,2) 2 (1,2) 2 (1,2) - 
 
As shown in table 3, the prescription of recommended treatment in CHF patients 
increased as the number of chronic conditions increased. For patients managed in 
primary care without attending hospital, prescription of ACEI/ARBs rose from 50.8 
to 83.5% for 0 and ≥ 4 comorbidities, respectively, and for ACEI/ARBs and BB 
from 13.1 to 30.6% for 0 and ≥ 4 comorbidities, respectively. In patients with 
hospitalization events during the follow-up period, prescription of ACEI/ARBs rose 
from 66.0 to 86.9% for 0 and ≥ 4 comorbidities, respectively, and for ACEI/ARBs 
and BB from 19.1 to 39.4% for 0 and ≥ 4 comorbidities, respectively. 
 
Table 3. Prescription according to the number of co-morbidities and hospitalization event 
 
Number of 
comorbidities 
Outcome Patients taking  
ACE/ARBs, n (%)
Patients taking 
ACE/ARBs and BB, n (%) 
0 (n=820) No hospital event (n=773) 393 (50.8) 101 (13.1) 
Hospital event (n=47) 31 (66.0) 9 (19.1) 
1 (n=2314) No hospital event (n=2149) 1625 (75.6) 391 (18.2) 
Hospital event (n=165) 131 (79.4) 43 (26.1) 
2 (n=2299) No hospital event (n=2122) 1725 (81.3) 509 (24.0) 
Hospital event (n=177) 158 (89.3) 52 (29.4) 
3 (n=1223) No hospital event (n=1066) 898 (84.2) 309 (29.0) 
Hospital event (n=157) 137 (87.3) 54 (34.4) 
≥4 (n=517) No hospital event (n=418) 349 (83.5) 128 (30.6) 
Hospital event (n=99) 86 (86.9) 39 (39.4) 
Table includes just patients with a drug prescription. Patients without a prescription are not included 
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The multivariable analysis (Table 4) was performed for the total sample size 
(n=7173) and confirmed that patients receiving more treatments were patients with 
3 comorbidities (odds ratio [OR] 5.10 [4.12–6.28] for ACEI/ARBs treatment and 
OR 2.67 [2.10–3.38)] for ACEI/ARBs and BB), and ≥ 4 comorbidities (OR 4.90 
[3.72–6.47] for ACEI/ARBs treatment and OR 2.95 [2.24–3.89] for ACEI/ARBs and 
BB), and patients with a hospital event during the follow-up (OR 1.47 [1.17–1.85) 
for ACEI/ARBs treatment and OR 1.41 [1.17–1.69] for ACEI/ARBs and BB). 
 
Table 4. Modelling analysis of the prescription of treatment 
 
 ACE/ARBs in the overall sample ACE/ARBs and BB in the overall sample 
 OR (95% CI) OR (95% CI) 
1 comorbidity  2.96 (2.50-3.50) 1.49 (1.18-1.86) 
2 comorbidity  4.27 (3.58-5.08) 2.07 (1.66-2.59) 
3 comorbidity  5.10 (4.12-6.28) 2.67 (2.10-3.38) 
4 comorbidity  4.90 (3.72-6.47) 2.95 (2.24-3.89) 
Hospital event 1.47 (1.17-1.85) 1.41 (1.17-1.69) 
Table shows that the odds of receiving drug treatment in a multivariable analysis increase as the number of 
comorbidities increases. Having a hospitalization event also increase the odds. 
 
The univariate analysis (Table 5) showed that comorbidities with higher numbers 
of ACEI/ARBs prescriptions were hypertension (OR 3.75 [3.33–4.22]), diabetes 
mellitus (OR 1.79 [1.57–2.04]), ischaemic heart disease (OR 1.25 [1.10–1.42]), 
hypercholesterolemia (OR 1.27 [1.04–1.56]) and CKD (OR 1.17 [1.00–1.37]). 
Those comorbidities with more ACEI/ARBs and BB prescriptions were ischaemic 
heart disease (OR 3.01 [2.68–3.38]), hypertension (OR 1.40 [1.23–1.59]), diabetes 
mellitus (OR 1.33 [1.18–1.49]) and hypercholesterolemia (OR 1.58 [1.32–1.89]). 
No significant changes were found when removing deceased patients from the 
analysis. Cluster analysis reported 0.5% (95% confidence interval [CI] 0.2–0.7) 
variability on prescription between PCPs. 
 
Table 5. Prescription for each condition (univariate model) 
 
 OR (95% CI) P value (LR test) 
ACE/ARBs   
AGE 0.99 (0.99-0.10) 0.003 
Gender (men) 1,02 (0.91-1.14) 0.705 
Hypercholesterolemia  1.27 (1.04-1.56) 0.019 
Hypertension  3.75 (3.33-4.22) <0.001 
Diabetes Mellitus  1.79 (1.57-2.04) <0.001 
Ischemic heart disease 1.25 (1.10-1.42) 0.001 
CKD  1.17 (1.00-1.37) 0.049 
COPD  0.91 (0.78-1.06) 0.229 
Region 0.94 (0.77-1.15) 0.528 
Hospital event 1.65 (1.32-2.06) <0.001 
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 OR (95% CI) P value (LR test) 
ACE/ARBs + BB 
AGE 0.96 (0.95-0.96) <0.001 
Gender (men) 1.62 (1.45-1.82) <0.001 
Hypercholesterolemia  1.58 (1.32-1.89) <0.001 
Hypertension  1.40 (1.23-1.59) <0.001 
Diabetes Mellitus  1.33 (1.18-1.49) <0.001 
Ischemic Heart Disease 3.01 (2.68-3.38) <0.001 
CKD  1.12 (0.96-1.30) 0.139 
COPD  0.63 (0.53-0.74) <0.001 
Region 0.93 (0.81-1.06) 0.290 
Hospital event 1.56 (1.30-1.86) <0.001 
Gender, COPD, and region have no effect on the odds of receiving ACE/ARBs. CKD and region has no 
effect on the odds of receiving ACE/ARBs and BB. For the rest, in a univariate analysis, having a specific 
condition increased the odds of drug prescription. 
 
Discussion 
In our cohort of patients from PCPs registered with the diagnosis of CHF, we found 
that the prescription of ACEI/ARBs and ACE/ARBs with BB increased as the 
number of comorbidities increased. These prescriptions were also more prevalent 
in patients who had attended hospital. Hypertension, diabetes mellitus and 
ischaemic heart disease were comorbid conditions significantly more associated 
with higher rates of prescribing. 
Previous studies which have compared the clinical performance of FPs against 
cardiologists have found that hospitalization and cardiologist care increased the 
odds of receiving ACEI and BB8,9,13,14,18. The justification self-reported by FPs 
includes difficulties with establishing a diagnosis and the lack of confidence in 
initiating treatment with ACEI, partly because of their adverse effects in patients 
who are often elderly and frail, with comorbidity and polypharmacy11. 
Nevertheless, our study showed that the relationship between FPs prescribing 
recommended treatments and the number of conditions remained positive, which 
suggests that FPs can provide equivalent care for more complex patients with 
greater comorbidities compared with less complex patients. Patients attending 
hospital had a higher probability of receiving treatment. 
Similar trends were found in a previous study that focused on the quality of care 
for several chronic conditions rather than a single disease19. In this study, a 
positive relationship between quality of care and the number of chronic conditions 
was found, probably because these patients had more opportunities to receive 
care. Also, patients who had seen a relevant specialist received higher quality of 
care. Another trial focusing on patients with CHF managed in primary care 
reported no association between the number of comorbidities and the prescription 
of evidence-based pharmacotherapy18. These different results could be explained 
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by differences in the comorbid conditions analyzed and how these were 
measured. 
Previous studies which have analysed the effect of comorbidities on prescribing 
have reported that a diagnosis of ischaemic heart disease increased the odds for 
prescription, whereas age and respiratory or pulmonary disease decreased it8,9,18. 
Our results were in line with this. We also reported a positive effect for 
hypertension and diabetes mellitus. 
Prescription rates achieved in our study were higher than previously reported. In 
2002, a European study involving FPs reported that in Spain prescription of 
diuretics was 63%, ACEI/ARBs was 51% and combined therapy with BB was 7%. 
In our study, prescription rose to 78.8% for diuretics, 77.1% for ACEI/ARBs and 
22.8% for combined therapy with BB8. This showed that adherence to evidence-
based pharmacotherapy had increased although there is still room for 
improvement. 
Our study had some limitations. First, we used a simple count of comorbid 
conditions as one of our primary predictor variables. This method has been used 
previously with the disadvantage that it is a crude measure of complexity, because 
clinicians do not view all coexisting conditions as equivalent in complexity19. We 
identified CHF patients through their FPs' electronic patient records and did not 
formally validate the diagnosis of CHF because of resource constraints. 
Furthermore, we did not have data to show how many patients had 
echocardiography performed, which would have confirmed the diagnosis and 
aetiology of CHF and helped in the interpretation of our results. 
Therefore, those patients with no hospital event during study follow-up and without 
a prescription of diuretics (22.4%) may have had an uncertain diagnosis of CHF. 
Nevertheless our aim was to report on FPs' clinical performance when prescribing 
in patients with multiple comorbidities, including those with an uncertain diagnosis 
of CHF because this is what happens in real practice. Also, it is important to take 
into account our context in which FPs usually register a diagnosis of CHF after 
specialist confirmation. Specialists are also involved in the diagnosis and 
management of these patients in the community, and have provided support to 
FPs as part of an integrated care program since 1990 (Table 1)20. Nevertheless, 
we could not identify the source of diagnosis and could not exclude that the 
diagnosis of CHF was made by FPs using clinical means alone. Furthermore, we 
could not report on the severity of the illness, either for the CHF diagnosis or 
comorbidities, so we may have underestimated the total disease burden. 
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Despite not having access to those PCPs excluded in the urban region, we 
assumed that other ethnic or socio-economic difference affecting outcomes (in the 
urban area) were minimized by our selection process which began from a 
randomization for a disease management intervention. 
 
Conclusions 
Prescription of recommended treatments in ambulatory patients with CHF 
increased as the number of comorbidities increased, regardless of hospitalization 
events. This study suggests that FPs can provide care to more complex patients 
which is equivalent to those that are less complex, as determined by the number 
of comorbidities. Further research should explore patient experiences with drugs, 
including intolerance, contra indications and overall patient willingness to adhere 
to treatment. This may highlight other barriers which can help physicians and 
managers on delivering care. 
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Main findings 
Section I Analysis of organization of coronary heart disease primary care 
The Epa Cardio project found substantial variation in the management of patients 
with coronary heart disease (CHD), in primary care, which was more related to 
differences between practices than between countries. Overall rates for the 
prescription of recommended preventive medicines (statins and antiplatelet 
therapy) were over 80%. Risk factors registration varied from 55% to over 90% for: 
physical activity, weight, smoking status, serum cholesterol and blood pressure 
(ordered from lowest minus to highest scores achieved). Intermediate patient 
outcomes, in terms of treatment targets for systolic blood pressure, diastolic blood 
pressure and LDL cholesterol were achieved in 46% (SD 21%), 86% (SD 12%) 
and 48% (SD 22%) of the patients respectively. 
A number of organizational characteristics of primary care practices were 
associated with the management of patients with CHD. Implementation of aspects 
of the chronic care model such as clinical information systems, self-management 
support, health care organization, decision support and delivery system design 
were associated to better risk factor registration, antiplatelet therapy and/or 
influenza vaccination. The delivery of community interventions on cardiovascular 
risk management was not associated to better cardiovascular risk management in 
patients with CHD. 
 
Section II Analysis of current practice in chronic heart failure primary care 
The study on computerised clinical practices in the primary care management of 
patients with chronic heart failure (CHF) in Catalonia provided insight into the 
trends and predictors of mortality, hospitalization, readmission and length of stay 
for patients in a Mediterranean community-based cohort. In this cohort 90% of 
patients with CHF managed in primary care survived after 1 year of the onset. 
Only 9.0% of patients were admitted to hospital in this time period due to 
cardiovascular reasons. During the follow up period we found that while the 
number of admissions and length of stay decreased, the number of readmissions 
increased. Elderly patients with co-morbidities were at highest risk of worst 
outcome for survival (diabetes mellitus - DM-, chronic obstructive pulmonary 
disease –COPD-, chronic kidney disease -CKD-, and ischemic heart disease – 
IHD-), hospitalization (DM, COPD and CKD), readmissions (DM, IHD and 
hypertension) and long length of stay in hospital (CKD, IHD, DM, hypertension and 
COPD). Prescription of ACEI/ARBs and ACE/ARBs + BB increased as the number 
of co-morbidities increased. These prescriptions were more prevalent in patients 
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who had been to hospital. Hypertension, DM and IHD were co-morbid conditions 
significantly more associated with higher rates of prescription.  
 
Discussion of the findings 
Section I Analysis of organization of coronary heart disease primary care 
Our findings regarding the quality of care of cardiovascular risk management were 
comparable to what is reported by other European Studies such as 
EUROASPIRE1 and SPHERE2. It may be noted that patients in these projects 
were from specialist care, while the EPA Cardio was done in primary care. Our 
data also conciliates with findings in a Cochrane review3. We found that practice 
size was not associated to better performance in cardiovascular care. In our 
sample across countries small practices were able to deliver a performance on 
cardiovascular risk management as good as larger practices and variation existed 
in both types of practices. In previous research on practice size no consistent 
results has been found. In general, studies based on national data show that 
larger practices tended to show better performance and provide more extensive 
services, for instance more preventive activities4-8; tended to be more cost-
effective and offers opportunities to develop skills and gives managerial 
advantages. On the other hand, there seemed to be a trade off between high 
quality clinical care and interpersonal care, and access seemed better in smaller 
practices5,9.  
While research evidence showed mixed results on the contribution of 
organizational components of chronic care model to patient outcomes, our 
research indicated that self-management support systems and clinical information 
systems were associated with better cardiovascular risk management but not with 
recorded intermediate patient outcomes. This is in line with what is previously 
published10. Although scarce research has been performed implementing 
community resources and health care organization elements to judge their relative 
effectiveness and to compare our results, we found that healthcare organization 
was associated to influenza vaccination while community interventions on 
cardiovascular risk reduction were associated neither to better cardiovascular risk 
management nor to intermediate patient outcomes. Reasons for that may remain 
in the organisation of provision of care. We evaluated community interventions in 
the Catalan health care system, which is characterised by broad implementation of 
most of the Chronic Care Model elements. Access to healthcare services could 
partly explain why community interventions for cardiovascular risk reduction to 
usual care did not show additional benefits. Implementing programs to enhance 
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healthy lifestyles in primary care has not been uniformly successful11. Variability in 
the literature could be explained by several factors such as patient selection, 
targeted population, type of intervention (individual or group counselling, health 
policies ...), service provider (primary care based or other community providers), 
and to the quality of the intervention itself (i.e. the quality of the counselling 
techniques used, targeted barriers, professionals’ skills...). Also several barriers 
associated to primary care professionals (lack of time, patient compliance, lack of 
counselling skills, costs...) and to  patients (dissatisfaction with the quality of 
counselling received by those working in primary care, lack of skills, lack of will 
power, strong sense of fatalism regarding the course of their disease...) have been 
associated to lack of success of lifestyle interventions. Although it remains unclear 
from the literature which provider should deliver such interventions, for instance 
primary health care or other community base providers, evidence suggests that 
the role that motivated family physicians could have on changing patients 
behaviours12 plus addressing individual as well as community-level elements13 are 
key factors to consider, which may suggest that care needs to be seen by the 
patient as a continuum to achieve effective interventions. 
 
Section II Analysis of current practice in chronic heart failure primary care 
In contrast with previous studies, that were done in hospital-based cohorts or 
selected patients from clinical trials, we included patients from a Mediterranean 
community-based cohort, taking into consideration the complexity in terms of 
patients' comorbidities that FPs face in primary care settings.  
Comparisons with other studies are difficult because of differences in patient 
selection, patient characteristics and periods of follow up. Nevertheless the data 
suggest that our survival rates were higher than those reported in the literature, 
either United States and Europe and in line with those reported by the Spanish 
national data registry from hospital-based heart failure clinics14. For instance 
higher than the Framingham15 (57% for men and 64% for women) and Rochester16 
(77%) studies in United States, and the Hillington17 (62%) study in Britain and in 
Netherlands (74% survival at one year)18. In contrast, in our cohort, we found a low 
rate of hypercholesterolemia and ischemic heart disease, which could partly 
explain our positive results on survival. Our hospitalisation rates due to 
cardiovascular reasons were lower compared to those previously reported in 
United States19 and England20. Reasons for that may remain in the organisation of 
provision of care. In Catalonia, the emphasis is on primary care management of 
chronic conditions in the community, with specialists supporting FPs and home 
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care. Nonetheless we found a high readmissions rate suggesting that 
management of CHF in the community may delay patient hospitalization up to a 
more severe stage when hospitalizations are more frequent. 
In relation to prescription of recommended treatment to patients with multi-
morbidity we found mixed results in the literature. Similar trends than us were 
reported by a previous study21 focussing not on a single disease but on several 
chronic conditions and quality of care. In this study a positive relationship between 
quality of care and the number of chronic conditions was found positive because 
these patients probably had more opportunities to receive care; also patients who 
had seen a relevant specialist received higher quality of care. Nevertheless 
another trial focussing on patients with CHF managed in primary care reported no 
association between the number of comorbidities and the prescription of evidence-
based pharmacotherapy22. These mix results could be explained by differences on 
the comorbid conditions analysed and how these were measured. 
Prescription rates found in our study (with data collection from 2005-2007) were 
higher than in 2002. An European study23 involving FPs reported that in Spain 
prescription of diuretics was 63%, ACEI/ARBs was of 51% and combined therapy 
with BB was of 7%, in our study prescription has risen up to 78.8% for diuretics, 
77.1% for ACEI/ARBs and 22.8% for combined therapy with BB. This implies that 
adherence to evidence based pharmacotherapy has increased although there is 
still room for improvement. 
Despite our good results in current practice outcomes (survival, hospitalization and 
prescription) we found similar predictors of worse prognosis than previous 
community-based studies. For instance ageing24, diabetes mellitus15,25,26, 
hospitalization27 and renal failure16,17,25,27 have also been identified to increase the 
risk of death in the literature. Hypertension has been also previously reported16 as 
a positive predictor for survival, probably due to the negative effect of low systolic 
blood pressure on prognosis described elsewhere17,25,27 rather than to the 
diagnosis of hypertension itself which is one of the causes of diastolic heart failure 
and more prevalent in women and elderly who usually have antecedent of 
hypertension for many years18,28,29. 
Matching with our results, Dunlay et al19 from a community perspective found 
diabetes mellitus and creatinine clearance as predictors for CHF hospitalization. 
We could not find studies from a community perspective analysing high risk profile 
for readmissions due to CHF and long length of stay. Nonetheless a hospital-
based study30 found also and effect of diabetes mellitus and ischemic heart 
disease on increasing readmissions. Previous studies which have analyzed the 
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effect of comorbidities on prescription reported that ischemic heart disease 
increased the odds for prescription31 while age22;23 and respiratory/pulmonary31 
disease decreased it. Our results were in the same line and we also reported a 
positive effect for hypertension and diabetes mellitus.  
 
Methodological considerations 
We used data from an European project (EPA Cardio project) to analyze 
organizational factors influencing management of coronary heart disease in 
primary care. In this project, first joined Austria, Belgium, Finland, France, 
Germany, the Netherlands, Slovenia, Switzerland, the UK. Spain (Catalonia 
region) joined later. Israel also participated in major parts of this study. To reduce 
bias due to differences in the organization of the health care systems of the 
participating countries concerning to practice size, accessibility to patients and 
medical records system implemented, countries were instructed to sample practice 
in such way that they mirrored the situation of their countries as much as possible. 
Stratification procedures were required to include practices in the study, according 
to number of FPs working in the practices and urbanization. Nonetheless figures 
for a country should not be considered representative for the national situation.  
Patient inclusion varied depending on access to patients. While most countries 
included a random sample of patients listed at the practice, some did it from those 
visited (France) or after a recall process (Austria, Switzerland and German). In 
Spain, two provinces (Girona and Barcelona) of the Catalan region participated in 
the study. Although practice inclusion was similar in both, patient selection 
differed. While in Barcelona all patients listed with one FP of each participating 
practice were included, in Girona a randomized selection of 15 patients were 
included. In both, data was extracted electronically, limiting results to those data 
recorded in a coded way. In the rest of countries data collection was done with a 
paper-based audit form and performed uniformly. Our patient inclusion criteria did 
not completely prevent heterogeneity within the study population. The cohort 
included patients who had a myocardial infarction or vascular surgery and have 
been treated in secondary care as well as patients with stable angina pectoris who 
might have been treated in primary care exclusively.  
Although the measures of the Chronic Care Model were post hoc constructed, 
they were evidence based and abstracted from the validated EPA instrument, 
which had been developed through a rigorous indicator development process and 
extensive testing32,33.  
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Differences across countries were considered in a multilevel analysis considering 
patients nested in practices, and practices nested in countries to allow valid 
conclusions. To some extent, the international focus of our study controlled 
variation across health care systems which allowed to achieve more robust 
conclusions.  
The study on chronic heart failure (CHF) in Catalonia had a number of limitations. 
We included patients newly diagnosed with a diagnosis code of CHF in the primary 
care electronic medical records and measured survival after the onset, 
cardiovascular admissions as primary diagnosis at discharge, and patients with 
prescription of angiotensin-converting enzyme inhibitors (ACEI) / angiotensin II 
receptor blockers (ARBs) and ACEI / ARBs + beta-blockers (BB) if not diagnosis of 
asthma. We also analysed the effect of comorbidities as prognostic factors. In our 
cohort, we found low prevalence of ischemic heart disease (27%) which may 
influenced our positive findings particularly on survival. Because of the low 
registration in the electronic medical records, we failed to report on severity and 
aetiology of CHF which could have influenced prognostic profile for survival and 
hospitalizations. Also prescription rates of BB. On the other hand, these are 
inherent limitations of studies using electronic medical records. Comorbidities were 
also identified through primary care electronic medical records and we were not 
able to capture how long patients were exposed to these conditions neither about 
severity by using bio-markers. When we analysed the association between 
prescription and comorbidities we used a simple count of comorbid conditions as 
one of our primary predictor variable. This method has been used previously21 with 
the disadvantage that it is a crude measure of complexity, since clinicians do not 
view all coexisting conditions as equivalent. Diagnosis accuracy was particularly 
relevant for the survival analysis, in this case we included just those patients on 
prescription of diuretics therefore probably missed patients with CHF not receiving 
diuretics. Regarding hospitalizations, we did not capture admissions to private 
hospitals or outside of targeted setting. However we included listed patients of 
PCPs with a hospital assigned. These patients rarely would go to private hospital 
or attend other PCPs or public hospital because of our continuum of care model. 
Data from the Government of Catalonia show that about 90% of patients use their 
assigned hospital34. 
Our analysis exploring patient outcomes in cardiovascular primary care included 
various strong elements, among others the large sample size, community based 
patient selection process and medical record audit from three regional data bases 
(mortality register, hospital database and electronic primary care medical records).  
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Implications for practice and future research 
In this thesis we focus on patients with established CVD, that is patients with CHF 
and patients with CHD. Our projects showed that patients managed in primary 
care obtained high quality of care, in terms of high survival rate, low 
hospitalisations rate and good rates of prescription of recommended treatment. 
Nevertheless there is still room for improvement, particularly on risk factors 
registration by FPs and patients' achievement of recommended levels of blood 
pressure and low density lipoprotein cholesterol (LDL). Our findings showed that 
some organizational components are associated to better cardiovascular care, 
which can help health planning and delivery and to orientate future research.  
 
Implications for practice 
• In our study larger practices (over two full time equivalent FP) delivered 
performance on cardiovascular risk management as good as small 
practices. In the Catalan primary healthcare system, size of primary care 
practices vary from 4 to 36 fte FP depending on a geographic definition of 
population attended. In our context, there is an increasing tendency to reduce 
the number of practices by enlarging existing ones. Certainly, larger primary 
care practices offer advantages for providing structured care to larger groups 
of patients, which may be cost effective and relevant for delivering preventive 
activities particularly in community orientated primary care systems delivering 
public health interventions. Also offer opportunities to develop skills by having 
chances of more experience and gives managerial advantages, especially 
when specialized staff is required. Nonetheless and extra effort might have to 
be done to deliver interpersonal care and ensure access to services provided, 
which have been reported to be better in smaller practices5,9. 
• Implementing some of the organizational components of the chronic 
care model can improve clinical performance on cardiovascular risk 
management in primary care. Our research conducted in several primary 
care systems across Europe supports that "clinical information systems", 
"health care organization elements" and "self-management support" are 
associated to better process indicators in preventive procedures. In the 
Catalan health care system, most of the components of the CCM are widely 
implemented35. The Catalan Health Institute, the main primary care provider, 
has a powerful electronic medical records system with specific devises 
implemented allowing chronic care management. For instance "clinical 
information systems" are implemented including computerized medical 
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records, prescription, referrals, examination requests and quality and safety 
management. "Health care organization elements" includes procedures for 
the management of patient information in relation to examination results, 
alerts in the electronic medical records for reviewing medication prescribed, 
monthly and annual production of quality reports among others. Nonetheless 
availability of these devises do not imply their use by primary care 
practitioners. For instance European research has shown35 that Catalan 
primary care practices score higher on implementing CCM components, 
nonetheless when comparing to other European countries our professionals 
perform in the average and our level of registration of cardiovascular risk 
factors was one of the lowest. An in depth evaluation of the current use by 
primary care practices of the electronic medical records system 
(understanding barriers and facilitators) and its association to patients 
outcomes and clinicians' performance may contribute to better quality of 
cardiovascular risk management.   
• Self-management support is another component of the CCM which have 
been associated to better care for cardiovascular risk management. It 
involves collaboratively helping patients and their families acquire the skills 
and confidence to manage their chronic illness36. Overall, in Catalan primary 
care practices self-management support is routinely provided among FPs35. 
For instance leaflets about cardiovascular disease (for example, CHD, stroke, 
hypertension, and stop smoking) usually are available for patients to take 
home or read at the practice. Practices usually also have an up-to-date 
directory of prevention activities/organizations available locally (for example, 
gyms, walking group, and weight-watchers), written information on lifestyle is 
usually given, and also advice about websites for education on health risks or 
healthy lifestyle. But this is an area not enough studied though well designed 
projects. Concomitantly, some practices also deliver complementary 
community interventions for lifestyle improvement which in our research have 
not been associated to additional benefits on cardiovascular risk 
management. A better understanding of how best lifestyle improvement for 
cardiovascular risk prevention should be delivered in our primary care 
orientated healthcare system could help to save duplications among 
providers. Evidence suggests that the role that motivated family physicians 
could have12 on changing patients behaviours plus addressing individual as 
well as community-level elements13 are key factors to consider.  
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• Our research shows that in Catalonia, primary care has proved to 
develop effective management of patients with existing cardiovascular 
disease (CHF) in terms of survival, low hospitalizations and medication 
of complex patients. Service planning and prevention programs should take 
into consideration that management of cardiovascular diseases in primary 
care can help to save costs of care delivery by reducing hospital admissions 
and decrease median of length of stay in hospital. On the other hand, it may 
delay hospitalizations up to a more severe stage when re-admissions are 
more frequent. The availability of tools to identify high risk patients for 
readmissions, considering predictors of worse prognosis for existing 
cardiovascular disease (CHF) and other co-morbidities would aid health 
planning.   
 
Future research 
• Further research is still needed to demonstrate effects of practice size on 
cost-effectiveness, also in patient outcomes and patient satisfaction, as well 
as achieving health targets, interpersonal care and access to family 
physicians. 
• Advantages of implementing multiple components of the CCM has been 
interpreted as supporting synergistic effects10, for instance community 
resources – i.e. exercise programs ‒ help patients acquire self-management 
skills36. Further research should demonstrate cost-effectiveness of 
implementing multiple CCM components rather than single one. For instance 
in the Catalan context, future research should be orientated to identify: (1) 
what CCM components are most used and which are not, (2) barriers and 
facilitators for their integration in clinical practice, and (3) the association of 
CCM component implementation with better cardiovascular risk management.  
• Further research is required to understand how lifestyle improvement for 
cardiovascular risk management should be delivered to improve patients 
outcomes and save costs.  
• Further research should develop tools to identify high risk patients for hospital 
readmissions either for existing cardiovascular diseases (CHF) and other 
comorbidities which could support professionals and health care 
management. Further developments in this field considering predictors of 
worse prognosis are required.   
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Chapter 1  
In the first chapter we introduce the topics of this thesis. Studies presented focus 
in patient outcomes, professional performance and practice characteristics and 
organization related to quality of care of cardiovascular management and 
secondary prevention in primary care. Patients with established cardiovascular 
diseases, CHD and CHF are considered.  
 
Chapter 2 
Primary care has an important role in cardiovascular risk management (CVRM) 
and a minimum size of scale of primary care practices may be needed for efficient 
delivery of CVRM. We examined CVRM in patients with coronary heart disease 
(CHD) in primary care and explored the impact of practice size. In an observational 
study in 8 countries we sampled CHD patients in primary care practices and 
collected data from electronic patient records. Practice samples were stratified 
according to practice size and urbanization; patients were selected using coded 
diagnoses when available. CVRM was measured on the basis of internationally 
validated quality indicators. In the analyses practice size was defined in terms of 
number of patients registered of visiting the practice. We performed multilevel 
regression analyses controlling for patient age and sex. We included 181 practices 
(63% of the number targeted). Two countries included a convenience sample of 
practices. Data from 2960 CHD patients were available. Some countries used 
methods supplemental to coded diagnoses or other inclusion methods introducing 
potential inclusion bias. We found substantial variation on all CVRM indicators 
across practices and countries. We computed aggregated practice scores as 
percentage of patients with a positive outcome. Rates of risk factor recording 
varied from 55% for physical activity as the mean practice score across all 
practices (SD 32%) to 94% (SD 10%) for blood pressure. Rates for reaching 
treatment targets for systolic blood pressure, diastolic blood pressure and LDL 
cholesterol were 46% (SD 21%), 86% (SD 12%) and 48% (SD 22%) respectively. 
Rates for providing recommended cholesterol lowering and antiplatelet drugs were 
around 80%, and 70% received influenza vaccination. Practice size was not 
associated to indicator scores with one exception: in Slovenia larger practices 
performed better. Variation was more related to differences between practices 
than between countries. We concluded that CVRM measured by quality indicators 
showed wide variation within and between countries and possibly leaves room for 
improvement in all countries involved. Few associations of performance scores 
with practice size were found. 
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Chapter 3 
Cardiovascular risk management (CVRM) received by patients shows large 
variation across countries. In this study we explored the aspects of primary care 
organization associated with key components of CVRM in coronary heart disease 
(CHD) patients. We designed an observational study including 273 primary care 
practices and a random sample of 4563 CHD patients from Austria, Belgium, 
England, Finland, France, Germany, The Netherlands, Slovenia, Switzerland and 
Spain. We performed an audit in primary care practices in 10 European countries 
and used six indicators to measure key components of CVRM: risk factor 
recording, antiplatelet therapy, influenza vaccination, blood pressure levels 
(systolic <140 and diastolic <90 mm Hg), and low-density lipoprotein cholesterol 
<2.5 mmol/l. Data from structured questionnaires were used to construct an overall 
measure and six domain measures of practice organization based on 39 items. 
Using multilevel regression analyses we explored the effects of practice 
organization on CVRM, controlling for patient characteristics. We found that better 
overall organization of a primary care practice was associated with higher scores 
on three indicators: risk factor registration (B=0.0307, p<0.0001), antiplatelet 
therapy (OR 1.05, p=0.0245) and influenza vaccination (OR 1.12, p<0.0001). 
Overall practice organization was not found to be related with recorded blood 
pressure or cholesterol levels. Only the organizational domains 'self-management 
support' and 'use of clinical information systems' were linked to three CVRM 
indicators. We concluded that a better organization of a primary care practice was 
associated with better scores on process indicators of CVRM in CHD patients, but 
not on intermediate patient outcome measures. Direct support for patients and 
clinicians seemed most influential. 
 
Chapter 4 
Linkage to community resources has been re-emphasized recently, but little is 
known about its impact on the quality and outcomes of prevention in primary care. 
In this study we aimed to assess whether primary care practices delivering 
community orientated programs to enhance healthy life styles had better scores on 
indicators of cardiovascular risk management in patients with coronary heart 
disease. We conducted an observational study in Catalonia (Spain), including 36 
practices, 36 professionals and 722 patients with coronary heart disease (37% 
female: mean age 72 (SD 11.73)). We used a structured questionnaire 
administered to professionals in these practices. The predictor variable of interest 
was reported participation in community orientated programs to enhance healthy 
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life styles such as physical exercise groups and stop smoking. We extracted 
patient data from electronic medical records regarding recorded risk factors, drug 
prescription and intermediate patient outcomes (blood pressure levels, low-density 
lipoprotein cholesterol, body mass index). We found that thirty practices delivered 
community programs. Most delivered one [17 (47.2%) practices] or two programs 
[11 (30.5%) practices]. The content of these programs was orientated to education 
and motivation to enhance healthy life styles, using group counselling sessions, 
mailed print material and one-to-one counselling. In practices delivering 
community programs more patients received anti-hypertensives (89.7%), 
antiplatelet therapy (80.5%) and statins (70.8%). However, none of the differences 
with the other practices were statistically significant. We concluded that in our 
setting, no evidence was found for the added value of community orientated 
programs on cardiovascular risk in patients with coronary heart disease.  
 
Chapter 5 
Scarce research has been performed in ambulatory patients with chronic heart 
failure in the Mediterranean area. In this study, we aimed to describe survival 
trends in our target population and the impact of prognostic factors. To achieve so, 
we carried out a population-based retrospective cohort study in Catalonia (north-
east Spain) of 5659 ambulatory patients [60% women; mean age 77 (10) years] 
with incident chronic heart failure. Eligible patients were selected from the 
electronic patient records of primary care practices from 2005 and were followed-
up until 2007. We found that during the follow-up period deaths occurred in 950 
patients (16.8%). Survival after the onset of chronic heart failure at 1, 2, and 3 
years was 90%, 80%, 69%, respectively. No significant differences in survival were 
found between men and women (P=.13). Cox proportional hazard modelling 
confirmed an increased risk of death with older age (hazard ratio=1.06; 95% CI, 
1.06-1.07), diabetes mellitus (hazard ratio=1.53; 95% CI, 1.33-1.76), chronic 
kidney disease (hazard ratio=1.73; 95% CI, 1.45-2.05), and ischemic heart 
disease (hazard ratio=1.18; 95% CI, 1.02-1.36). Hypertension (hazard ratio=0.73; 
95% CI, 0.64-0.84) had a protective effect. Our results suggested that service 
planning and prevention programs should take into consideration the relatively 
high survival rates found in our area and the effect of prognostic factors that can 
help to identify high risk patients. 
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Chapter 6 
Little is known on predictors of hospitalization in ambulatory patients with chronic 
heart failure, and known predictors may not apply to Mediterranean countries. In 
this study we aimed to document longitudinal trends in hospitalizations and identify 
patient-related predictors of hospital admission, re-admission and length of stay in 
the targeted population. We conducted a population-based retrospective cohort 
study in Catalonia (North-East Spain), including 7196 ambulatory patients (58.6% 
women; mean age 76 years). Eligible patients were selected from the electronic 
patient records of primary care practices, and followed for 3 years. We found that 
at 3 years of follow up overall 645 (9.0%) patients had cardiovascular 
hospitalization, 37% were readmitted, and median length of stay was 9 
(interquartile range 5-17) days. Chronic kidney disease [odds ratio (OR)=1.98 
(1.62-2.43)], IHD [OR=1.72 (1.45-2.04)], DM [OR=1.50 (1.27-1.78)] and chronic 
obstructive pulmonary disease [OR=1.43 (1.16-1.77)] increased the risk for 
hospitalisation. DM [OR=1.70 (1.22-2.38)], IHD [OR=1.85 (1.33-2.58)] and HTA 
[OR=1.66 (1.11-2.46)] increased the risk for readmissions. Chronic kidney disease 
[OR of 2.21 (1.70-2.90)], IHD [OR of 2.19 (1.73-2.77)], DM [OR=1.70 (1.34-2.15)], 
HTA [OR=1.51 (1.13-2.01)], chronic obstructive pulmonary disease [OR=1.37 
(1.02-1.83)] increased the risk for long length of stay in hospital. This study 
identified predictors of hospitalization, readmissions and long length of stay which 
can help clinicians and managers to identify high risk patients which should be 
targeted on service planning and when designing preventive actions. 
 
Chapter 7  
Multimorbidity and polypharmacy pose challenges to the improvement of the 
quality of care. In this study we aimed to determine the association between 
prescription of recommended treatment in ambulatory patients with chronic heart 
failure and multiple comorbidities and hospitalization events. We conducted a 
population-based retrospective cohort study in Catalonia (North-East Spain), 
including 7173 newly registered patients with chronic heart failure [59% women; 
mean age 76.3 (SD 10.7) years]. Patients were selected from the electronic patient 
records of primary care practices and followed for three years. Our main measures 
were prescription of angiotensin-converting enzyme inhibitors (ACEI) / angiotensin 
II receptor blockers (ARBs) and beta-blockers (BB). We found that prescription of 
ACEI/ARBs in patients managed in primary care without hospitalization event 
during the follow up rose from 50.8% to 83.5% for 0 and ≥4 comorbidities 
respectively and for ACE/ARBs + BB from 13.1% to 30.6% for 0 and ≥ 4 
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comorbidities respectively. Patients with a hospitalization event were more often 
treated (ACEI/ARBs, OR 1.47; [1.17-1.85]; ACEI/ARBs + BB, OR 1.41; [1.17-
1.69]). Comorbid conditions receiving more treatment were hypertension 
(ACEI/ARBs, OR 3.75 [3.33-4.22]; ACEI/ARBs + BB, OR 1.40 [1.23-1.59]), 
diabetes mellitus (ACEI/ARBs, OR 1.79 [1.57-2.04]; ACEI/ARBs + BB, OR 1.33 
[1.18-1.49]) and ischemic heart disease (ACEI/ARBs, OR 1.25 [1.10-1.42]; 
ACEI/ARBs + BB, OR 3.01 [2.68-3.38]). Our results reported that prescription of 
recommended treatment in patients with chronic heart failure increased as the 
number of comorbidities increase; and suggested that family physicians can 
provide equivalent care to more complex patients and to those less complex, 
according to the number of comorbidities. 
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Hoofdstuk 1 
In het eerste hoofdstuk introduceren we de onderwerpen die behandeld worden in 
dit proefschrift. De gepresenteerde studies zijn gericht op patiëntuitkomsten, 
professioneel handelen alsook de eigenschappen en de organisatie van de 
praktijken gerelateerd aan kwaliteit van zorg van cardiovasculair management en 
secundaire preventie in de eerstelijnszorg. We keken daarbij naar patiënten bij wie 
cardiovasculaire aandoeningen, CHD en CHF zijn vastgesteld.     
 
Hoofdstuk 2 
De eerstelijnszorg speelt een belangrijke rol in cardiovasculair risicomanagement 
(CVRM), waarbij een minimale grootte van de schaal van eerstelijnspraktijken 
nodig kan zijn om doelmatige CVRM zorg te leveren. We onderzochten CVRM bij 
patiënten met coronaire hartziekten (CHD) in de eerstelijnszorg en keken daarbij 
naar het effect van de grootte van de praktijk. Voor een observatiestudie in acht 
landen kozen we steekproefsgewijs CHD-patiënten uit in eerstelijnspraktijken en 
verzamelden data uit elektronische patiëntendossiers. De steekproeven werden 
vervolgens gestratificeerd met inachtneming van de grootte van de praktijk en de 
mate van verstedelijking; bij het selecteren van de patiënten werden waar mogelijk 
gecodeerde diagnoses gebruikt. CVRM werd gemeten op basis van internationaal 
gevalideerde kwaliteitsindicatoren. In de analyses werd de grootte van de praktijk 
gedefinieerd op basis van het aantal geregistreerde patiënten dat de praktijk 
bezoekt. We voerden multilevel regression analyses uit, waarbij we corrigeerden 
voor leeftijd en geslacht van de patiënten bij 181 praktijken (63% van het aantal 
dat we als doel hadden). In twee landen hebben we een steekproef op basis van 
een gemakkelijke bereikbaarheid van praktijken geïncludeerd. We hadden de 
beschikking over data van 2.960 CHD-patiënten. In enkele landen werden 
methodes gebruikt die een aanvulling vormden op de gecodeerde diagnoses of 
werden andere inclusiemethoden gebruikt, waardoor potentiële inclusiebias 
mogelijk was. Bij alle CVRM-indicatoren vonden we een substantiële variatie in de 
verschillende praktijken en landen. We berekenden de gezamenlijke praktijkscores 
als percentage patiënten met een positief resultaat. Scores voor het registreren 
van risicofactoren varieerden van 55% voor fysieke activiteiten als gemiddelde 
praktijkscore in alle praktijken (SD 32%) tot 94% (SD 10%) voor bloeddruk. Cijfers 
voor het behalen van behandelingsdoelen voor systolische bloeddruk, diastolische 
bloeddruk en LDL cholesterol waren respectievelijk 46% (sd 21%), 86% (SD 12%) 
en 48% (SD 22%). Cijfers voor het leveren van aanbeloven vermindering van het 
cholesterol en antiplatelet medicijnen lagen rond de 80%, en 70% ontving een 
 Samenvatting 123 
antigriepprik. De grootte van de praktijk hield geen verband met de 
indicatorscores, met een uitzondering: in Slovenië presteerden grotere praktijken 
beter. De variatie had meer betrekking op verschillen tussen de praktijken 
onderling dan tussen landen. Onze conclusie was dat CVRM gemeten met 
kwaliteitsindicatoren veel variatie liet zien in en tussen landen, en dat het mogelijk 
gelegenheid biedt voor verbetering in alle betrokken landen. We vonden weinig 
verband tussen prestatiescores en grootte van de praktijken.               
 
Hoofdstuk 3 
Cardiovasculair risicomanagement (CVRM), zoals dat gegeven wordt aan 
patiënten, laat een grote variatie zien in landen. In deze studie hebben we 
aspecten van de eerstelijnszorg onderzocht die geassocieerd worden met 
belangrijke componenten van CVRM bij patiënten met coronaire hartziekten 
(CHD). We hebben daartoe een observatiestudie opgezet met daarin 273 
eerstelijnspraktijken en een willekeurige steekproef van 4.563 CHD-patiënten uit 
Oostenrijk, België, Engeland, Finland, Frankrijk, Duitsland, Nederland, Slovenië, 
Zwitserland en Spanje. In eerstelijnspraktijken in tien Europese landen hebben we 
een audit uitgevoerd, waarbij we zes indicatoren gebruikten om belangrijke 
componenten van CVRM te meten: vastleggen van risicofactoren, behandeling 
met antiplatelet medicijnen, griepvaccinaties, hoogte van de bloeddruk (systolisch 
<140 en diastolisch <90 mm Hg), en lipoproteïne cholesterol met lage dichtheid 
<2.5 mmol/l. Data uit gestructureerde vragenlijsten werden gebruikt om een 
totaalmeting te maken, alsook om zes domeinmetingen van de praktijkorganisatie 
te maken op basis van 39 items. Door mulitlevel regressieanalyses toe te passen 
konden we de resultaten van de praktijkorganisaties met betrekking tot CVRM 
onderzoeken, daarbij corrigerend voor patiëntkarakteristieken. We ontdekten dat 
een betere algehele organisatie van de eerstelijnspraktijk verband hield met 
hogere scores voor drie indicatoren: registratie van risicofactoren (B=0.0307, 
p<0.0001), behandeling met antiplatelet medicijnen (OR 1.05, p=0.0245) en 
griepvaccinaties (OR 1.12, p<0.0001). De algehele praktijkorganisatie werd niet in 
verband gebracht met de geregistreerde hoogte van de bloeddruk of het 
cholesterol. Alleen de organisatorische domeinen 'zelfmanagement ondersteuning' 
en 'gebruik van klinische informatiesystemen' waren gelinkt aan drie CVRM 
indicatoren. Onze conclusie was dat een betere organisatie van de 
eerstelijnspraktijk in verband gebracht werd met betere scores bij 
procesindicatoren van CVRM bij CHD-patiënten, maar niet bij tussentijdse 
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resultaten van patiëntuitkomsten. Rechtstreekse ondersteuning van patiënten en 
clinici lijkt de meeste invloed te hebben. 
 
Hoofdstuk 4 
Recentelijk is het belang van een koppeling met gemeenschapsbronnen 
benadrukt, maar er is nog weinig bekend over de impact op de kwaliteit en de 
uitkomsten van preventie in de eerstelijnszorg. In deze studie probeerden we vast 
te stellen of eerstelijnspraktijken die gemeenschapsprogramma's organiseren 
gericht op het verhogen van een gezonde leefstijl, betere scores behaalden op de 
indicatoren voor cardiovasculair risicomanagement bij patiënten met coronaire 
hartziekten. Daartoe voerden we een observatiestudie uit in Catalonië (Spanje), bij 
36 praktijken, 36 zorgverleners en 722 patiënten met een coronaire hartziekte 
(37% vrouwelijk: gemiddelde leeftijd 72 (SD 11.73)). De zorgverleners in deze 
praktijken ontvingen een gestructureerde vragenlijst. De voorspellende variabele 
van belang hierbij was deelname aan gemeenschapsgeoriënteerde programma's, 
gericht op het verhogen van een gezonde leefstijl, zoals fysieke 
inspanningsgroepen en stoppen-met-rokengroepen. Uit patiëntendata haalden we 
elektronische medische gegevens die betrekking hadden op vastgelegde 
risicofactoren, voorgeschreven medicijnen en tussentijdse patiëntuitkomsten 
(hoogte van de bloeddruk, lipoproteïne cholesterol met lage dichtheid, body mass 
index). Dertig praktijken bleken gemeenschapsprogramma's te leveren. De 
meerderheid daarvan leverde een [17 (47.2%) praktijken] of twee programma's [11 
(30.5%) praktijken]. De inhoud van deze programma's richtte zich op onderwijs en 
motivatie om een gezonde leefstijl na te streven, daarbij gebruik makend van 
counseling sessies in groepen, geprinte materialen die met de post verstuurd 
werden en een-op-een counseling. Bij praktijken die gemeenschapsprogramma's 
boden ontvingen meer patiënten bloeddrukverlagende middelen (89,7%), 
behandeling met antiplateletmedicijnen (80,5%) en statines (70,8%). Echter, de 
verschillen met de andere praktijken waren statistisch gezien niet significant. Onze 
conclusie was dan ook dat er in onze setting geen bewijs was gevonden voor de 
toegevoegde waarde van gemeenschapsgeoriënteerde programma's over 
cardiovasculaire risico's bij patiënten met coronaire hartziekten.       
 
Hoofdstuk 5 
Er is amper onderzoek gedaan bij niet-bedlegerige patiënten met chronisch 
hartfalen in het gebied rond de Middellandse Zee. In deze studie richtten we ons 
op het beschrijven van overlevingstendensen in onze doelgroep, alsook op de 
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impact van voorspellende factoren. Om dit te bereiken voerden we een 
retrospectieve cohort studie uit op basis van populatie in Catalonië (noordoost 
Spanje) met 5.659 niet-bedlegerige patiënten (60% vrouwen; gemiddelde leeftijd 
77 [10] jaar) met inherent chronisch hartfalen. Geschikte patiënten werden 
geselecteerd uit de elektronische patiëntendossiers van de eerstelijnspraktijken 
vanaf 2005 en werden gevolgd tot 2007. We ontdekten dat er zich gedurende de 
follow-up periode 950 sterfgevallen voordeden (16,8%). Overleving na het begin 
van chronisch hartfalen bij 1, 2 en 3 jaar was respectievelijk 90%, 80% en 69%. Er 
werden geen significante verschillen in overleving gevonden tussen mannen en 
vrouwen (P=.13). Cox proportional hazard modelling bevestigde een toegenomen 
risico op sterven bij toegenomen leeftijd (hazard ratio=1,06; 95% 
betrouwbaarheidsinterval, 1,06-1,07), diabetes mellitus (hazard ratio=1,53; 95% 
BI, 1,33-1,76), chronische nierziekte (hazard ratio=1,73; 95% BI, 1,45-2,05), en 
ischemische hartaandoening (hazard ratio=1,18; 95% BI, 1,02-1,36). Hoge 
bloeddruk (hazard ratio=0,73; 95% BI, 0,64-0,84) bleek een beschermend effect te 
hebben. Onze uitkomsten suggereren dat er bij het plannen van diensten en 
preventieprogramma's rekening moet worden gehouden met de relatief hoge 
overlevingscijfers die in ons gebied gevonden worden en het effect van 
voorspellende factoren die kunnen helpen bij het identificeren van 
hoogrisicopatiënten.  
 
Hoofdstuk 6 
Er is weinig bekend over de voorspellers van ziekenhuisopname bij niet-
bedlegerige patiënten met chronisch hartfalen, en bestaande voorspellers zijn 
wellicht niet van toepassing op de landen rond de Middellandse Zee. Ons doel in 
dit onderzoek was het vastleggen van longitudinale trends in ziekenhuisopnames. 
Tevens probeerden we de patiëntgerelateerde voorspellers van 
ziekenhuisopnames, heropnames en duur van de opname in de beoogde 
populatie te identificeren. Daartoe voerden we een bevolkingsonderzoek uit door 
middel van een retrospectieve cohort studie in Catalonië (noordoost Spanje), 
inclusief 7.196 niet-bedlegerige patiënten (58,6% vrouwen; gemiddelde leeftijd 
76 jaar). Uit de elektronische patiëntgegevens van de huisartsenpraktijken werden 
geschikte patiënten geselecteerd, die vervolgens gevolgd werden voor een 
periode van drie jaar. We ontdekten dat er na drie jaar follow-up bij in totaal 645 
(9,0%) patiënten sprake was van cardiovasculaire ziekenhuisopname, 37% werd 
opnieuw opgenomen, en de gemiddelde lengte van de opname was 9 
(interkwartielafstand 5-17) dagen. Toegenomen risico op ziekenhuisopname werd 
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veroorzaakt door chronische nierziekten [odds ratio (OR)=1,98 (1,62-2,43)], IHD 
[OR=1,72 (1,45-2,04)], DM [OR=1,50 (1,27-1,78)] en chronische obstructieve 
longziekten (COPD) [OR=1,43 (1,16-1,77)]. DM [OR=1,70 (1,22-2,38)], IHD 
[OR=1,85 (1,33-2,58)] en HTA [OR=1.66 (1.11-2.46)]. Chronische nierziekten [OR 
van 2,21 (1,70-2,90)], IHD [OR van 2,19 (1,73-2,77)], DM [OR=1,70 (1,34-2,15)], 
HTA [OR=1,51 (1,13-2,01)] en chronische obstructieve longziekten [OR=1,37 
(1,02-1,83)] zorgden voor een toename in het risico van een langdurige 
ziekenhuisopname. In dit onderzoek identificeerden we voorspellers van 
ziekenhuisopnames, heropnames en lange verblijfsduur, die clinici en managers 
kunnen helpen in het vaststellen van hoogrisicopatiënten. Deze patiënten kunnen 
dan gericht benaderd worden voor service planning en bij het opstellen van 
preventieve handelingen.   
 
Hoofdstuk 7 
Multimorbiditeit en polyfarmacie vormen een uitdaging voor het verbeteren van de 
kwaliteit van zorg. In deze studie hebben we geprobeerd om het verband vast te 
stellen tussen het voorschrijven van de aanbevolen behandeling bij niet-
bedlegerige patiënten met chronisch hartfalen en multipele comorbiditeit en 
ziekenhuisopnames. Daartoe voerden we een bevolkingsonderzoek uit door 
middel van een retrospectieve cohort studie in Catalonië (noordoost Spanje), 
inclusief 7.173 nieuw geregistreerde patiënten met chronisch hartfalen (59% 
vrouwen; gemiddelde [SD] leeftijd 76,3 [10,7] jaar). De patiënten werden uit de 
elektronische patiëntgegevens van de huisartspraktijken geselecteerd en 
gedurende drie jaar gevolgd. We gebruikten de voorgeschreven ACE-remmers 
angiotensin-converting enzyme inhibitors (ACEI) / angiotensin II receptor blockers 
(ARBs) en beta-blockers (BB) als uitgangspunt in onze metingen. We ontdekten 
dat het voorschrijven van ACEI/ARBs bij patiënten in de eerstelijnszorg zonder 
ziekenhuisopname gedurende follow-up steeg van respectievelijk 50,8% naar 
83,5% voor 0 en ≥ 4 comorbiditeiten, en voor ACE/ARBs + BB van 
respectievelijk13,1% naar 30,6% voor 0 en ≥4 comorbiditeiten. Patiënten die 
opgenomen waren in het ziekenhuis werden vaker behandeld (ACEI/ARBs, OR 
1,47; [1,17-1,85]; ACEI/ARBs + BB, OR 1,41; [1,17-1,69]). Comorbide 
aandoeningen die vaker behandeld werden waren hoge bloeddruk (ACEI/ARBs, 
OR 3,75 [3,33-4,22]; ACEI/ARBs + BB, OR 1,40 [1,23-1,59]), diabetes mellitus 
(ACEI/ARBs, OR 1,79 [1,57-2,04]; ACEI/ARBs + BB, OR 1,33 [1,18-1,49]) en 
ischemische hartaandoeningen (ACEI/ARBs, OR 1,25 [1,10-1,42]; ACEI/ARBs + 
BB, OR 3,01 [2,68-3,38]). Onze resultaten laten een toename zien in het 
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voorschrijven van de aanbevolen behandeling bij patiënten met chronisch 
hartfalen, tegelijk met een toename van het aantal comorbiditeiten. We stellen 
daarom voor dat huisartsen gelijke zorg leveren aan zowel complexe als minder 
complexe patiënten, al naargelang het aantal comorbiditeiten.     
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